Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
22,000 | 2023-12-02 00:00:00 UTC | 2 Dividend Stocks to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/2-dividend-stocks-to-buy-and-hold-forever-2 | null | null | Over long periods, dividend stocks tend to outperform their non-dividend-paying counterparts. There are likely several reasons for this, one of which is that sustaining a dividend program requires a solid underlying business. So corporations that are able to consistently pay dividends and raise their payouts tend to ha... | Since it is already a Dividend King, it would be unlikely for AbbVie management to skip an annual increase or cut the payout if that could be avoided, as to do so would mean being kicked out of that exclusive club. And with that in mind, let's consider two dividend stocks worth holding onto now: AbbVie (NYSE: ABBV) and... | And with that in mind, let's consider two dividend stocks worth holding onto now: AbbVie (NYSE: ABBV) and Visa (NYSE: V). AbbVie AbbVie's dividend profile looks great on paper. AbbVie's yield at its current share price is 4.48%, compared to the S&P 500's average of 1.62%. | And with that in mind, let's consider two dividend stocks worth holding onto now: AbbVie (NYSE: ABBV) and Visa (NYSE: V). AbbVie AbbVie's dividend profile looks great on paper. AbbVie's yield at its current share price is 4.48%, compared to the S&P 500's average of 1.62%. | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! And with that in mind, let's consider two dividend stocks worth holding onto now: AbbVie (NYSE: ABBV) and Visa (NYSE: V). AbbVie AbbVie's dividend profile looks great on paper. |
22,001 | 2023-12-02 00:00:00 UTC | 5 S&P 500 Stocks That Pay a Generous Dividend | ABBV | https://www.nasdaq.com/articles/5-sp-500-stocks-that-pay-a-generous-dividend | null | null | The S&P 500 is the benchmark for the investing world. This well-known index comprises 500 of the largest and most visible corporations in the United States, the world's leading economy.
It's also a great hunting ground for phenomenal long-term stock ideas to fit any investing strategy. Dividend investors are a large gr... | AbbVie Pharmaceuticals are a lucrative industry, especially if the company manages to develop a blockbuster drug. AbbVie (NYSE: ABBV) was a significant benefactor for several years from the success of Humira, the world's top-selling drug. AbbVie has become a favorite among dividend investors. | AbbVie Pharmaceuticals are a lucrative industry, especially if the company manages to develop a blockbuster drug. AbbVie (NYSE: ABBV) was a significant benefactor for several years from the success of Humira, the world's top-selling drug. AbbVie has become a favorite among dividend investors. | AbbVie Pharmaceuticals are a lucrative industry, especially if the company manages to develop a blockbuster drug. AbbVie (NYSE: ABBV) was a significant benefactor for several years from the success of Humira, the world's top-selling drug. AbbVie has become a favorite among dividend investors. | AbbVie Pharmaceuticals are a lucrative industry, especially if the company manages to develop a blockbuster drug. AbbVie (NYSE: ABBV) was a significant benefactor for several years from the success of Humira, the world's top-selling drug. AbbVie has become a favorite among dividend investors. |
22,002 | 2023-12-01 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-26 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,003 | 2023-12-01 00:00:00 UTC | Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-abbv-to-buy-immunogen-nvs-ups-mid-term-sales-view-more | null | null | This week, AbbVie ABBV announced a definitive agreement to acquire cancer biotech Immunogen at a premium valuation of $10.1 billion. Novartis NVS raised its mid-term sales growth outlook by 1%. Sanofi SNY and partner Regeneron’s second phase III chronic obstructive pulmonary disease (COPD) study showed that their block... | AbbVie announced positive top-line data from the phase II LUMINOSITY study evaluating telisotuzumab-vedotin, also called Teliso-V, for patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression. This week, AbbVie ABBV announced a definitive agreement to acquire cancer biotech Immunoge... | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. This week, AbbVie ABBV announced a definitive agreemen... | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. This week, AbbVie ABBV announced a definitive agreemen... | Image Source: Zacks Investment Research In the last five trading sessions, AbbVie rose the most (2.8%) while Novo Nordisk declined the most (1.4%). This week, AbbVie ABBV announced a definitive agreement to acquire cancer biotech Immunogen at a premium valuation of $10.1 billion. Recap of the Week’s Most Important Stor... |
22,004 | 2023-11-30 00:00:00 UTC | Health Care Sector Update for 11/30/2023: SNGX, IMGN, ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-11-30-2023%3A-sngx-imgn-abbv | null | null | Health care stocks were higher Thursday afternoon, with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.7%.
The iShares Biotechnology ETF (IBB) rose 1.1%.
In corporate news, Soligenix (SNGX) shares soared 183% after it said Thursday the US Food and Drug Administration has c... | AbbVie (ABBV) and ImmunoGen (IMGN) said Thursday that they have signed an agreement for AbbVie to buy ImmunoGen and its ovarian cancer therapy Elahere. ImmunoGen shares surged 83% and AbbVie was up 2.4%. The iShares Biotechnology ETF (IBB) rose 1.1%. | ImmunoGen shares surged 83% and AbbVie was up 2.4%. AbbVie (ABBV) and ImmunoGen (IMGN) said Thursday that they have signed an agreement for AbbVie to buy ImmunoGen and its ovarian cancer therapy Elahere. Health care stocks were higher Thursday afternoon, with the NYSE Health Care Index adding 0.7% and the Health Care S... | AbbVie (ABBV) and ImmunoGen (IMGN) said Thursday that they have signed an agreement for AbbVie to buy ImmunoGen and its ovarian cancer therapy Elahere. ImmunoGen shares surged 83% and AbbVie was up 2.4%. Health care stocks were higher Thursday afternoon, with the NYSE Health Care Index adding 0.7% and the Health Care S... | AbbVie (ABBV) and ImmunoGen (IMGN) said Thursday that they have signed an agreement for AbbVie to buy ImmunoGen and its ovarian cancer therapy Elahere. ImmunoGen shares surged 83% and AbbVie was up 2.4%. Health care stocks were higher Thursday afternoon, with the NYSE Health Care Index adding 0.7% and the Health Care S... |
22,005 | 2023-11-30 00:00:00 UTC | AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio | ABBV | https://www.nasdaq.com/articles/abbvie-to-buy-immunogen-for-%2410.1-billion-to-boost-cancer-drug-portfolio | null | null | Adds details throughout
Nov 30 (Reuters) - AbbVie ABBV.N said on Thursday it will buy drugmaker ImmunoGen IMGN.O for $10.1 billion, boosting its presence in the market for cancer treatments.
The drugmaker will pay $31.26 per ImmunoGen share in cash, representing a premium of 94.6% to the last closing price.
This transa... | Adds details throughout Nov 30 (Reuters) - AbbVie ABBV.N said on Thursday it will buy drugmaker ImmunoGen IMGN.O for $10.1 billion, boosting its presence in the market for cancer treatments. This transaction is expected to close in the middle of 2024, AbbVie said. The drugmaker will pay $31.26 per ImmunoGen share in ca... | Adds details throughout Nov 30 (Reuters) - AbbVie ABBV.N said on Thursday it will buy drugmaker ImmunoGen IMGN.O for $10.1 billion, boosting its presence in the market for cancer treatments. This transaction is expected to close in the middle of 2024, AbbVie said. The drugmaker will pay $31.26 per ImmunoGen share in ca... | Adds details throughout Nov 30 (Reuters) - AbbVie ABBV.N said on Thursday it will buy drugmaker ImmunoGen IMGN.O for $10.1 billion, boosting its presence in the market for cancer treatments. This transaction is expected to close in the middle of 2024, AbbVie said. The drugmaker will pay $31.26 per ImmunoGen share in ca... | Adds details throughout Nov 30 (Reuters) - AbbVie ABBV.N said on Thursday it will buy drugmaker ImmunoGen IMGN.O for $10.1 billion, boosting its presence in the market for cancer treatments. This transaction is expected to close in the middle of 2024, AbbVie said. The drugmaker will pay $31.26 per ImmunoGen share in ca... |
22,006 | 2023-11-30 00:00:00 UTC | AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln | ABBV | https://www.nasdaq.com/articles/abbvie-to-acquire-immunogen-for-%2431.26-shre-in-all-cash-deal-of-about-%2410.1-bln | null | null | (RTTNews) - AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
Under the terms of the transaction, ... | (RTTNews) - AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's... | (RTTNews) - AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). Under the terms of the transaction, ... | (RTTNews) - AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). Under the terms of the transaction, ... | Under the terms of the transaction, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash. As a fast-growing solid tumor therapy, ELAHERE provides AbbVie with a potential multi-billion-dollar on-market medicine with expansion opportunities in the ovarian cancer market. (RTTNews) - AbbVie ... |
22,007 | 2023-11-30 00:00:00 UTC | AbbVie Should Consider a Dividend Cut -- Here's Why | ABBV | https://www.nasdaq.com/articles/abbvie-should-consider-a-dividend-cut-heres-why | null | null | Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. These special companies have raised their dividends for at least 50 years, and AbbVie inherit... | In short, AbbVie's yield, which is almost 3x higher than the S&P 500 average, doesn't bode well for its share-price appreciation prospects in the near term, especially with the company's top and bottom lines moving in the wrong direction. Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been th... | Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. These special companies have raised their dividends for at least 50 years, and AbbVie inherit... | Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. These special companies have raised their dividends for at least 50 years, and AbbVie inherit... | Second, AbbVie stock has been highly prized among investors for its all-star dividend program. Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings... |
22,008 | 2023-11-30 00:00:00 UTC | Health Care Sector Update for 11/30/2023: IMGN, ABBV, XENE, CALT, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-11-30-2023%3A-imgn-abbv-xene-calt-xlv-ibb | null | null | Health care stocks were gaining premarket Thursday with the iShares Biotechnology ETF (IBB) advancing by 0.7% recently while the Health Care Select Sector SPDR Fund (XLV) was up 0.3%.
ImmunoGen (IMGN) was rallying by over 83% amid an agreement for AbbVie (ABBV) to acquire ImmunoGen and its ovarian cancer therapy Elaher... | ImmunoGen (IMGN) was rallying by over 83% amid an agreement for AbbVie (ABBV) to acquire ImmunoGen and its ovarian cancer therapy Elahere. Health care stocks were gaining premarket Thursday with the iShares Biotechnology ETF (IBB) advancing by 0.7% recently while the Health Care Select Sector SPDR Fund (XLV) was up 0.3... | ImmunoGen (IMGN) was rallying by over 83% amid an agreement for AbbVie (ABBV) to acquire ImmunoGen and its ovarian cancer therapy Elahere. Health care stocks were gaining premarket Thursday with the iShares Biotechnology ETF (IBB) advancing by 0.7% recently while the Health Care Select Sector SPDR Fund (XLV) was up 0.3... | ImmunoGen (IMGN) was rallying by over 83% amid an agreement for AbbVie (ABBV) to acquire ImmunoGen and its ovarian cancer therapy Elahere. Health care stocks were gaining premarket Thursday with the iShares Biotechnology ETF (IBB) advancing by 0.7% recently while the Health Care Select Sector SPDR Fund (XLV) was up 0.3... | ImmunoGen (IMGN) was rallying by over 83% amid an agreement for AbbVie (ABBV) to acquire ImmunoGen and its ovarian cancer therapy Elahere. Health care stocks were gaining premarket Thursday with the iShares Biotechnology ETF (IBB) advancing by 0.7% recently while the Health Care Select Sector SPDR Fund (XLV) was up 0.3... |
22,009 | 2023-11-30 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-jj-eli-lilly-pfizer | null | null | For Immediate Release
Chicago, IL – November 30, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, J&J JNJ, Eli... | Stocks recently featured in the blog include: AbbVie ABBV, J&J JNJ, Eli Lilly LLY, Pfizer PFE. Some of the key players are AbbVie, J&J, Eli Lilly, Pfizer, Novartis, Merck, Sanofi, Gilead and Amgen. AbbVie has one of the strongest portfolios of immunology drugs and pipeline candidates. | Stocks recently featured in the blog include: AbbVie ABBV, J&J JNJ, Eli Lilly LLY, Pfizer PFE. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analys... | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog in... | Stocks recently featured in the blog include: AbbVie ABBV, J&J JNJ, Eli Lilly LLY, Pfizer PFE. Some of the key players are AbbVie, J&J, Eli Lilly, Pfizer, Novartis, Merck, Sanofi, Gilead and Amgen. AbbVie has one of the strongest portfolios of immunology drugs and pipeline candidates. |
22,010 | 2023-11-30 00:00:00 UTC | Is it a Good Idea to Invest in Harpoon (HARP) Stock Now? | ABBV | https://www.nasdaq.com/articles/is-it-a-good-idea-to-invest-in-harpoon-harp-stock-now | null | null | Harpoon Therapeutics HARP develops a novel class of T cell engagers, leveraging its proprietary Tri-specific T cell Activating Construct (TriTAC) platform. The company has made significant progress in the development of its key pipeline candidates, HPN328 and HPN217, in recent months.
In October, Harpoon Therapeutics p... | Earlier, AbbVie ABBV had an option agreement to in-license the worldwide exclusive license to the HPN217 program. However, in September, AbbVie terminated the option agreement and Harpoon now exclusively owns the program. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report... | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Harpoon Therapeutics, Inc. (HARP) : Free Stock Analysis Report To read this article on Zacks.com click here. Earlier, Abb... | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Harpoon Therapeutics, Inc. (HARP) : Free Stock Analysis Report To read this article on Zacks.com click here. Earlier, Abb... | Earlier, AbbVie ABBV had an option agreement to in-license the worldwide exclusive license to the HPN217 program. However, in September, AbbVie terminated the option agreement and Harpoon now exclusively owns the program. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report... |
22,011 | 2023-11-30 00:00:00 UTC | AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-posts-encouraging-data-from-lung-cancer-study | null | null | AbbVie ABBV announced top-line data from the single-arm phase II LUMINOSITY study on its investigational antibody-drug conjugate (ADC) candidate, telisotuzumab-vedotin (Teliso-V), in previously treated non-small cell lung cancer (NSCLC) patients with c-Met overexpression.
Management split its analysis between patients ... | AbbVie ABBV announced top-line data from the single-arm phase II LUMINOSITY study on its investigational antibody-drug conjugate (ADC) candidate, telisotuzumab-vedotin (Teliso-V), in previously treated non-small cell lung cancer (NSCLC) patients with c-Met overexpression. AbbVie is conducting an early-stage study evalu... | AbbVie ABBV announced top-line data from the single-arm phase II LUMINOSITY study on its investigational antibody-drug conjugate (ADC) candidate, telisotuzumab-vedotin (Teliso-V), in previously treated non-small cell lung cancer (NSCLC) patients with c-Met overexpression. Click to get this free report AstraZeneca PLC (... | These results were lower than the interim results shared by AbbVie last year in January, wherein response rates of 53.8% and 25% were reported across c-Met high and c-Met intermediate patients, respectively. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks ... | These results were lower than the interim results shared by AbbVie last year in January, wherein response rates of 53.8% and 25% were reported across c-Met high and c-Met intermediate patients, respectively. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks ... |
22,012 | 2023-11-30 00:00:00 UTC | Health Care Sector Update for 11/30/2023: JNJ, SNGX, ABBV, IMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-11-30-2023%3A-jnj-sngx-abbv-imgn | null | null | Health care stocks were advancing late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.9%.
The iShares Biotechnology ETF (IBB) rose 1.1%.
In corporate news, Johnson & Johnson's (JNJ) MedTech unit said Thursday it has completed the $400 million acquisit... | AbbVie (ABBV) and ImmunoGen (IMGN) said Thursday that they have signed an agreement for AbbVie to buy ImmunoGen and its ovarian cancer therapy Elahere. ImmunoGen shares surged 82% and AbbVie was up 2.8%. In corporate news, Johnson & Johnson's (JNJ) MedTech unit said Thursday it has completed the $400 million acquisitio... | AbbVie (ABBV) and ImmunoGen (IMGN) said Thursday that they have signed an agreement for AbbVie to buy ImmunoGen and its ovarian cancer therapy Elahere. ImmunoGen shares surged 82% and AbbVie was up 2.8%. Health care stocks were advancing late Thursday afternoon, with the NYSE Health Care Index and the Health Care Selec... | AbbVie (ABBV) and ImmunoGen (IMGN) said Thursday that they have signed an agreement for AbbVie to buy ImmunoGen and its ovarian cancer therapy Elahere. ImmunoGen shares surged 82% and AbbVie was up 2.8%. Health care stocks were advancing late Thursday afternoon, with the NYSE Health Care Index and the Health Care Selec... | ImmunoGen shares surged 82% and AbbVie was up 2.8%. AbbVie (ABBV) and ImmunoGen (IMGN) said Thursday that they have signed an agreement for AbbVie to buy ImmunoGen and its ovarian cancer therapy Elahere. Health care stocks were advancing late Thursday afternoon, with the NYSE Health Care Index and the Health Care Selec... |
22,013 | 2023-11-30 00:00:00 UTC | This Combination of 3 Stocks Provides Monthly Income | ABBV | https://www.nasdaq.com/articles/this-combination-of-3-stocks-provides-monthly-income | null | null | Receiving steady dividend payouts is always a great feeling, as paydays are always the best. Of course, most dividends are paid quarterly.
However, by targeting companies that pay out dividends in different months, investors can construct a portfolio that allows them to get paid monthly.
For example –
The first stock p... | The acquisition is expected to accelerate AbbVie’s entry into the commercial market for ovarian cancer, anticipated to close in the middle of 2024 and valued at roughly $10.1 billion. Interestingly enough, three stocks – Cardinal Health CAH, AbbVie ABBV, and Archer Daniels Midland ADM – would allow investors to reap a ... | When combined, all three stocks above – Cardinal Health CAH, AbbVie ABBV, and Archer Daniels Midland ADM – construct a portfolio that allows monthly income. Click to get this free report Archer Daniels Midland Company (ADM) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report AbbVie Inc... | When combined, all three stocks above – Cardinal Health CAH, AbbVie ABBV, and Archer Daniels Midland ADM – construct a portfolio that allows monthly income. Click to get this free report Archer Daniels Midland Company (ADM) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report AbbVie Inc... | Interestingly enough, three stocks – Cardinal Health CAH, AbbVie ABBV, and Archer Daniels Midland ADM – would allow investors to reap a monthly income. AbbVie AbbVie enjoys leadership positions in key therapeutic areas, including immunology, hematologic oncology, neuroscience, aesthetics, eye care, and women’s health. ... |
22,014 | 2023-11-30 00:00:00 UTC | Why Abbvie Stock Popped Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-popped-today | null | null | The big asset buy in the healthcare industry provided a healthy pop to the two companies involved on Thursday. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV), enjoyed a nearly 3% lift after the news was announced, contrasting quite favorably to the sagging S&P 500 index's 0.7% slip.
AbbVie is buying ... | The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV), enjoyed a nearly 3% lift after the news was announced, contrasting quite favorably to the sagging S&P 500 index's 0.7% slip. The deal should close next year In the press release, AbbVie and ImmunoGen revealed that the boards of directors of both compani... | AbbVie is buying ImmunoGen Before market open that day, AbbVie and ImmunoGen (NASDAQ: IMGN) announced in a joint press release that the former company is to acquire the latter. The deal should close next year In the press release, AbbVie and ImmunoGen revealed that the boards of directors of both companies approved the... | AbbVie is buying ImmunoGen Before market open that day, AbbVie and ImmunoGen (NASDAQ: IMGN) announced in a joint press release that the former company is to acquire the latter. AbbVie is eager to expand its presence in this field; in the press release, the company's CEO, Richard Gonzalez, was quoted as saying that the ... | The deal should close next year In the press release, AbbVie and ImmunoGen revealed that the boards of directors of both companies approved the acquisition. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV), enjoyed a nearly 3% lift after the news was announced, contrasting quite favorably to the saggin... |
22,015 | 2023-11-30 00:00:00 UTC | AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker | ABBV | https://www.nasdaq.com/articles/abbvie-stock-nyse%3Aabbv%3A-bet-on-a-smart-drugmaker-and-dealmaker | null | null | Is AbbVie (NYSE:ABBV) a drugmaker to wager on now? I believe it's a very smart move to consider buying a few shares, especially in light of recent positive news about AbbVie. So, I am bullish on ABBV stock because there are identifiable catalysts that could lead to major share price appreciation.
AbbVie is a large Amer... | It's often been considered a relatively safe company to invest in, and passive income seekers are certainly happy to collect AbbVie's hefty dividend distributions every quarter. Furthermore, AbbVie anticipates that Elahere will provide the company with a "potential multi-billion-dollar on-market medicine with expansion... | Specifically, AbbVie disclosed positive results from a Phase 2 clinical trial for Teliso-V, a cancer drug. Encouragingly, AbbVie found a "compelling" 35% overall response rate in patients with c-Met High and a 23% response rate in patients with c-Met intermediate. AbbVie Makes Significant Acquisition for Promising Canc... | If and when AbbVie gets FDA approval for this cancer treatment, ABBV stock would probably shoot higher immediately. AbbVie Makes Significant Acquisition for Promising Cancer Therapies As it turns out, Teliso-V and Livmoniplimab won't be the only notable cancer therapy candidates in AbbVie's pipeline. That's because the... | I believe it's a very smart move to consider buying a few shares, especially in light of recent positive news about AbbVie. AbbVie Makes Significant Acquisition for Promising Cancer Therapies As it turns out, Teliso-V and Livmoniplimab won't be the only notable cancer therapy candidates in AbbVie's pipeline. In other w... |
22,016 | 2023-11-29 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-11 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,017 | 2023-11-29 00:00:00 UTC | Medtronic Stock: Bull vs. Bear | ABBV | https://www.nasdaq.com/articles/medtronic-stock%3A-bull-vs.-bear-0 | null | null | Medtronic (NYSE: MDT) is a medical device giant that has generated billions of dollars in earnings over time thanks to its diabetes, cardiovascular, neuroscience, and medical-surgical platforms. The company's growth stagnated in recent years, though, so management set out on a path to transform the business -- with a f... | (AbbVie immediately jumps to mind.) Keith Speights has positions in AbbVie. Medtronic (NYSE: MDT) is a medical device giant that has generated billions of dollars in earnings over time thanks to its diabetes, cardiovascular, neuroscience, and medical-surgical platforms. | (AbbVie immediately jumps to mind.) Keith Speights has positions in AbbVie. A bullish view on Medtronic Adria Cimino: Though Medtronic stock hasn't yet taken off, there's reason to believe that could happen down the road -- and lead to lasting gains. | (AbbVie immediately jumps to mind.) Keith Speights has positions in AbbVie. A bullish view on Medtronic Adria Cimino: Though Medtronic stock hasn't yet taken off, there's reason to believe that could happen down the road -- and lead to lasting gains. | (AbbVie immediately jumps to mind.) Keith Speights has positions in AbbVie. As a result, the company's dividend should be viewed as more important than its growth. |
22,018 | 2023-11-29 00:00:00 UTC | 4 Large Drug Stocks to Watch as IBD Market Gains Traction | ABBV | https://www.nasdaq.com/articles/4-large-drug-stocks-to-watch-as-ibd-market-gains-traction | null | null | In recent years, there has been a surge in the prevalence of gastrointestinal disorders, particularly inflammatory bowel disease (IBD). It includes two conditions, Crohn's disease (“CD") and ulcerative colitis (“UC”), both characterized by chronic inflammation in the gastrointestinal tract.
There has been a consistent ... | Some of the key players are AbbVie ABBV, J&J JNJ, Eli Lilly LLY, Pfizer PFE, Novartis, Merck, Sanofi, Gilead and Amgen. AbbVie has one of the strongest portfolios of immunology drugs and pipeline candidates. AbbVie expects combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $17.5 billion by 2025 and mo... | Some of the key players are AbbVie ABBV, J&J JNJ, Eli Lilly LLY, Pfizer PFE, Novartis, Merck, Sanofi, Gilead and Amgen. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (... | AbbVie expects combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $17.5 billion by 2025 and more than $21 billion by 2027 J&J also boasts a strong immunology portfolio with drugs like Stelara and Tremfya. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (P... | AbbVie has one of the strongest portfolios of immunology drugs and pipeline candidates. Some of the key players are AbbVie ABBV, J&J JNJ, Eli Lilly LLY, Pfizer PFE, Novartis, Merck, Sanofi, Gilead and Amgen. AbbVie expects combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $17.5 billion by 2025 and mo... |
22,019 | 2023-11-29 00:00:00 UTC | Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy | ABBV | https://www.nasdaq.com/articles/mastering-market-trends%3A-the-7-best-blue-chip-stocks-for-todays-economy | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Blue chip stocks are generally a strong investment for any stage of the economic cycle and tend to take advantage of overarching trends. That remains as true today as it was yesterday and will be tomorrow. Today’s economy is marked by a lot of unsteadiness.... | AbbVie (ABBV) AbbVie (NYSE:ABBV) exemplifies how pharmaceutical firms can best navigate the inherent product cycles within the sector. The drug anchors AbbVie’s rheumatology segment, which declined by 11.3%. The point here is simple: AbbVie posted better-than-expected results during the quarter. | AbbVie (ABBV) AbbVie (NYSE:ABBV) exemplifies how pharmaceutical firms can best navigate the inherent product cycles within the sector. The drug anchors AbbVie’s rheumatology segment, which declined by 11.3%. The point here is simple: AbbVie posted better-than-expected results during the quarter. | AbbVie (ABBV) AbbVie (NYSE:ABBV) exemplifies how pharmaceutical firms can best navigate the inherent product cycles within the sector. The drug anchors AbbVie’s rheumatology segment, which declined by 11.3%. The point here is simple: AbbVie posted better-than-expected results during the quarter. | AbbVie (ABBV) AbbVie (NYSE:ABBV) exemplifies how pharmaceutical firms can best navigate the inherent product cycles within the sector. The drug anchors AbbVie’s rheumatology segment, which declined by 11.3%. The point here is simple: AbbVie posted better-than-expected results during the quarter. |
22,020 | 2023-11-28 00:00:00 UTC | 3 Defensive Dividend Stocks to Protect Your Portfolio | ABBV | https://www.nasdaq.com/articles/3-defensive-dividend-stocks-to-protect-your-portfolio | null | null | After a historically bad performance during the first half of the year, dividend stocks have come under quite a bit of scrutiny lately. A new Bloomberg analysis of the dividend stock underperformance in 2023 observed, “Investors wanted exposure to companies with a history of paying out profits as a precaution amid the ... | In 2023, AbbVie's stock is down about 10% on the year, due in large part to declining sales of its key drug, Humira - which faces stiff competition from biosimilars after losing patent protection. www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. ... | The average analyst rating for AbbVie is a "Moderate Buy," with 8 “Strong Buys” and 2 “Moderate Buys" outweighing 8 “Hold” ratings. www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. Specializing in pharmaceutical research and development, AbbVie f... | www.barchart.com AbbVie stands out with a strong dividend record, offering a quarterly dividend of $1.55 per share, backed by over a decade of growth. www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. Specializing in pharmaceutical research and de... | www.barchart.com Despite these challenges, including a decline in Botox sales, AbbVie remains fundamentally robust, with a diverse product portfolio and significant investment in research and development. www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) i... |
22,021 | 2023-11-28 00:00:00 UTC | Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp-0 | null | null | Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on 06/23/2005.
An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transpare... | Looking at individual holdings, Amgen Inc (AMGN) accounts for about 6.45% of total assets, followed by Eli Lilly & Co (LLY) and Abbvie Inc (ABBV). Click to get this free report Invesco Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock... | Click to get this free report Invesco Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceutical... | Click to get this free report Invesco Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceutical... | Looking at individual holdings, Amgen Inc (AMGN) accounts for about 6.45% of total assets, followed by Eli Lilly & Co (LLY) and Abbvie Inc (ABBV). Click to get this free report Invesco Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock... |
22,022 | 2023-11-28 00:00:00 UTC | AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-lymphoma-drug-gets-fda-breakthrough-therapy-tag | null | null | AbbVie ABBV along with partner Genmab GMAB announcedthat the FDA has granted breakthrough therapy designation (“BTD”) to epcoritamab for treating adults with relapsed or refractory (“R/R”) follicular lymphoma (“FL”), after two or more lines of therapies.
The FDA grants BTD to expedite the development and review of ther... | Alongside the above news, AbbVie and Genmab also announced that the European Medicines Agency (“EMA”) has validated a regulatory filing for epcoritamab in the same indication. AbbVie and Genmab are evaluating epcoritamab both as a monotherapy and as a combination regimen across lines of therapy in a range of hematologi... | Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report Genmab A/S Sponsored ADR (GMAB) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV along with... | AbbVie ABBV along with partner Genmab GMAB announcedthat the FDA has granted breakthrough therapy designation (“BTD”) to epcoritamab for treating adults with relapsed or refractory (“R/R”) follicular lymphoma (“FL”), after two or more lines of therapies. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Ran... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie ABBV along with partner Genmab GMAB announcedthat the FDA has granted breakthrough therapy designation (“BTD”) to epcoritamab for treating adults with relapsed or refractory (“R/R”) fol... |
22,023 | 2023-11-27 00:00:00 UTC | AbbVie, Genmab Issue Positive FDA, EMA Updates For Epcoritamab To Treat R/R Follicular Lymphoma | ABBV | https://www.nasdaq.com/articles/abbvie-genmab-issue-positive-fda-ema-updates-for-epcoritamab-to-treat-r-r-follicular | null | null | (RTTNews) - Drug makers AbbVie (ABBV) and Genmab (GMAB) announced Monday positive updates from the U.S. Food and Drug Administration or FDA and European Medicines Agency or EMA for epcoritamab (Epkinly / Tepkinly) for relapsed or refractory (R/R) follicular lymphoma (FL).
Epcoritamab, co-developed by AbbVie and Genmab,... | Epcoritamab, co-developed by AbbVie and Genmab, is an investigational T-cell engaging bispecific antibody administered subcutaneously for R/R FL, a complex blood cancer with limited treatment options. (RTTNews) - Drug makers AbbVie (ABBV) and Genmab (GMAB) announced Monday positive updates from the U.S. Food and Drug A... | (RTTNews) - Drug makers AbbVie (ABBV) and Genmab (GMAB) announced Monday positive updates from the U.S. Food and Drug Administration or FDA and European Medicines Agency or EMA for epcoritamab (Epkinly / Tepkinly) for relapsed or refractory (R/R) follicular lymphoma (FL). Mariana Cota Stirner, vice president, therapeut... | (RTTNews) - Drug makers AbbVie (ABBV) and Genmab (GMAB) announced Monday positive updates from the U.S. Food and Drug Administration or FDA and European Medicines Agency or EMA for epcoritamab (Epkinly / Tepkinly) for relapsed or refractory (R/R) follicular lymphoma (FL). Epcoritamab, co-developed by AbbVie and Genmab,... | Epcoritamab, co-developed by AbbVie and Genmab, is an investigational T-cell engaging bispecific antibody administered subcutaneously for R/R FL, a complex blood cancer with limited treatment options. (RTTNews) - Drug makers AbbVie (ABBV) and Genmab (GMAB) announced Monday positive updates from the U.S. Food and Drug A... |
22,024 | 2023-11-27 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-25 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,025 | 2023-11-26 00:00:00 UTC | 3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later | ABBV | https://www.nasdaq.com/articles/3-fantastic-dividend-stocks-to-buy-sooner-rather-than-later | null | null | Are you a pro when it comes to procrastination? Some investors take so long to make a decision on buying stocks that they miss out on great upside moves. And when those stocks pay juicy dividends, they also miss out on income.
Three Motley Fool contributors think they've found fantastic dividend stocks to buy sooner ra... | Anyone paying attention, though, should also know that AbbVie already has two newer autoimmune disease drugs (Rinvoq and Skyrizi) on the market that should, together, significantly exceed Humira's peak annual sales by 2027. Anyone paying attention would also know that AbbVie fully expects to return to what CFO Rob Mich... | Here's why they chose AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Gilead Sciences (NASDAQ: GILD). A bright future Keith Speights (AbbVie): You could look at where things stand right now for AbbVie and decide to avoid this stock. So is AbbVie's share price. | Here's why they chose AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Gilead Sciences (NASDAQ: GILD). A bright future Keith Speights (AbbVie): You could look at where things stand right now for AbbVie and decide to avoid this stock. So is AbbVie's share price. | Here's why they chose AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Gilead Sciences (NASDAQ: GILD). A bright future Keith Speights (AbbVie): You could look at where things stand right now for AbbVie and decide to avoid this stock. So is AbbVie's share price. |
22,026 | 2023-11-24 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-24 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,027 | 2023-11-24 00:00:00 UTC | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-10 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned -4.6% over the past month versus the Zacks S&P 500 composite's +8.2% change. The Zacks ... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie be... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #2 (Buy). AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gain... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #2 (Buy). AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gain... | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 1% over this period. AbbVie is expected to post earnings of $2.92 per share for the current quarter, representing a year-over-year change of -18.9%. |
22,028 | 2023-11-24 00:00:00 UTC | Could AbbVie Stock Help You Become a Millionaire? | ABBV | https://www.nasdaq.com/articles/could-abbvie-stock-help-you-become-a-millionaire | null | null | If you want an investment to make you a millionaire, you need three things. The first is some decent money to invest in the stock market, ideally at least $20,000. The second is time and patience -- big returns don't come quickly unless you're taking on significant risks. The third is an above-average return, which com... | AbbVie is facing some challenges ahead, particularly as its top-selling drug Humira generates less revenue due to rising competition. Plenty of growth on the horizon What's appealing about AbbVie's business is that although it's in the midst of a transition, with immunology drugs Skyrizi and Rinvoq replacing Humira and... | You can buy the stock at a discount Investors are discounting AbbVie's stock today, and that can be a huge advantage for growth investors looking for a stock to hold on to for the long haul as it could help secure big returns later on. But even if it's unsuccessful, AbbVie can still make for a solid growth stock to buy... | You can buy the stock at a discount Investors are discounting AbbVie's stock today, and that can be a huge advantage for growth investors looking for a stock to hold on to for the long haul as it could help secure big returns later on. 10 stocks we like better than AbbVie When our analyst team has a stock tip, it can p... | You can buy the stock at a discount Investors are discounting AbbVie's stock today, and that can be a huge advantage for growth investors looking for a stock to hold on to for the long haul as it could help secure big returns later on. Overall, however, AbbVie is well-funded and is generating strong enough cash flow th... |
22,029 | 2023-11-23 00:00:00 UTC | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-wisdomtree-u.s.-high-dividend-etf-dhs-be-on-your-investing-radar-10 | null | null | Launched on 06/16/2006, the WisdomTree U.S. High Dividend ETF (DHS) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.07 billion, making it one of the average sized E... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.84% of total assets, followed by Chevron Corp (CVX) and Abbvie Inc (ABBV). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.84% of total assets, followed by Chevron Corp (CVX) and Abbvie Inc (ABBV). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.84% of total assets, followed by Chevron Corp (CVX) and Abbvie Inc (ABBV). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... |
22,030 | 2023-11-23 00:00:00 UTC | Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth | ABBV | https://www.nasdaq.com/articles/dual-powerhouses%3A-7-dividend-stocks-marrying-high-yield-with-high-growth | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While it’s always important to consider passive-income providers, they often lack an underlying growth impetus, which subsequently makes the concept of high-yield dividend growth stocks so compelling. You can get your growth and also enjoy dividend payments... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com As I’ve mentioned many times before, I dig pharmaceutical giant AbbVie (NYSE:ABBV) for its Allergan acquisition. Through the buyout, AbbVie now controls Botox, a highly potent neurotoxic protein used for smoothing wrinkles. That’s a huge fundamental catalyst t... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com As I’ve mentioned many times before, I dig pharmaceutical giant AbbVie (NYSE:ABBV) for its Allergan acquisition. Through the buyout, AbbVie now controls Botox, a highly potent neurotoxic protein used for smoothing wrinkles. That’s a huge fundamental catalyst t... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com As I’ve mentioned many times before, I dig pharmaceutical giant AbbVie (NYSE:ABBV) for its Allergan acquisition. Through the buyout, AbbVie now controls Botox, a highly potent neurotoxic protein used for smoothing wrinkles. That’s a huge fundamental catalyst t... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com As I’ve mentioned many times before, I dig pharmaceutical giant AbbVie (NYSE:ABBV) for its Allergan acquisition. Through the buyout, AbbVie now controls Botox, a highly potent neurotoxic protein used for smoothing wrinkles. That’s a huge fundamental catalyst t... |
22,031 | 2023-11-22 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-10 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,032 | 2023-11-21 00:00:00 UTC | 3 "Boring" Stocks That Could Make You Rich | ABBV | https://www.nasdaq.com/articles/3-boring-stocks-that-could-make-you-rich | null | null | You don't have to invest exclusively in the so-called "exciting" stocks to get rich. Actually, the stocks that generate the most excitement for investors over the short term can often be big losers over the long term.
Of course, the amount of wealth needed to feel rich will be different for different investors. And no ... | In addition, AbbVie's product lineup includes several other rising stars such as migraine drugs Qulipta and Ubrelvy and antipsychotic therapy Vraylar. Like AbbVie and Ares Capital, Enterprise Products Partners rewards investors handsomely through its dividends (which, as a limited partnership, the company refers to as ... | Like AbbVie and Ares Capital, Enterprise Products Partners rewards investors handsomely through its dividends (which, as a limited partnership, the company refers to as distributions). See the 10 stocks *Stock Advisor returns as of November 20, 2023 Keith Speights has positions in AbbVie, Ares Capital, and Enterprise P... | Like AbbVie and Ares Capital, Enterprise Products Partners rewards investors handsomely through its dividends (which, as a limited partnership, the company refers to as distributions). See the 10 stocks *Stock Advisor returns as of November 20, 2023 Keith Speights has positions in AbbVie, Ares Capital, and Enterprise P... | AbbVie It could be tempting to view AbbVie (NYSE: ABBV) as a has-been. As a result, AbbVie's revenue, profits, and share price have fallen in 2023. AbbVie should still make long-term investors a lot of money, though. |
22,033 | 2023-11-21 00:00:00 UTC | Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now | ABBV | https://www.nasdaq.com/articles/ignore-eli-lilly.-these-2-stocks-are-better-buys-right-now | null | null | All eyes have been on Eli Lilly (NYSE: LLY) in recent times as it prepared to increase its earnings potential in the billion-dollar weight-loss treatment market. Lilly already has generated blockbuster revenue from Mounjaro, a diabetes drug doctors have also prescribed for weight loss. And now growth may really take of... | AbbVie also sells a variety of other blockbusters in areas including neuroscience, oncology, and aesthetics that could add to growth over time. Lilly's revenue climbed in the double digits in the most recent quarter, and the company isn't facing the same headwinds as Pfizer and AbbVie. AbbVie AbbVie (NYSE: ABBV) also f... | AbbVie AbbVie (NYSE: ABBV) also faces a pretty big challenge today, but like Pfizer, the pharma giant entered this moment with tools to spur a new era of growth. Now, though, sales are declining for the product, and that's clearly weighing on AbbVie's earnings. In the most recent quarter, Humira sales fell 36% to $3.5 ... | AbbVie AbbVie (NYSE: ABBV) also faces a pretty big challenge today, but like Pfizer, the pharma giant entered this moment with tools to spur a new era of growth. Lilly's revenue climbed in the double digits in the most recent quarter, and the company isn't facing the same headwinds as Pfizer and AbbVie. Now, though, sa... | Why are Pfizer and AbbVie better buys? AbbVie AbbVie (NYSE: ABBV) also faces a pretty big challenge today, but like Pfizer, the pharma giant entered this moment with tools to spur a new era of growth. Now, though, sales are declining for the product, and that's clearly weighing on AbbVie's earnings. |
22,034 | 2023-11-21 00:00:00 UTC | J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant | ABBV | https://www.nasdaq.com/articles/jj-jnj-seeks-expanded-use-of-lung-cancer-drug-rybrevant | null | null | Johnson & Johnson JNJ announced that it submitted a supplemental biologics license application (sBLA) seeking approval for the expanded use of its cancer drug, Rybrevant (amivantamab-vmjw).
The sBLA seeks Rybrevant's approval in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of patients wi... | Some better-ranked stocks in the healthcare sector are Novo Nordisk A/S NVO, AbbVie Inc. ABBV and Acadia Pharmaceuticals Inc. ACAD, carrying a Zacks Rank #2 (Buy) each at present. In the past 60 days, estimates for AbbVie’s 2023 earnings per share have improved from $11 to $11.19. Year to date, shares of ABBV have lost... | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks i... | Some better-ranked stocks in the healthcare sector are Novo Nordisk A/S NVO, AbbVie Inc. ABBV and Acadia Pharmaceuticals Inc. ACAD, carrying a Zacks Rank #2 (Buy) each at present. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVi... | Some better-ranked stocks in the healthcare sector are Novo Nordisk A/S NVO, AbbVie Inc. ABBV and Acadia Pharmaceuticals Inc. ACAD, carrying a Zacks Rank #2 (Buy) each at present. In the past 60 days, estimates for AbbVie’s 2023 earnings per share have improved from $11 to $11.19. Year to date, shares of ABBV have lost... |
22,035 | 2023-11-21 00:00:00 UTC | Should You Invest in AbbVie (ABBV) Based on Bullish Wall Street Views? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-abbvie-abbv-based-on-bullish-wall-street-views | null | null | When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Before we discuss the reliability of brokerage recommendations... | Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about AbbVie (ABBV). AbbVie currently has an average brokerage recommendation (ABR) of 1.92, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the... | AbbVie currently has an average brokerage recommendation (ABR) of 1.92, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall... | AbbVie currently has an average brokerage recommendation (ABR) of 1.92, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for AbbV... | Brokerage Recommendation Trends for ABBV Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about AbbVie (ABBV). AbbVie currently has an average brokerage recommendation (ABR) of 1.92, on a scale of 1 to 5 (Strong Buy... |
22,036 | 2023-11-21 00:00:00 UTC | ABBV vs. LLY: Which Stock Should Value Investors Buy Now? | ABBV | https://www.nasdaq.com/articles/abbv-vs.-lly%3A-which-stock-should-value-investors-buy-now | null | null | Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both AbbVie (ABBV) and Eli Lilly (LLY). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
We have found that the best way to discover great value opportunit... | Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both AbbVie (ABBV) and Eli Lilly (LLY). AbbVie has a Zacks Rank of #2 (Buy), while Eli Lilly has a Zacks Rank of #3 (Hold) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both AbbVie (ABBV) and Eli Lilly (LLY). AbbVie has a... | These metrics, and several others, help ABBV earn a Value grade of B, while LLY has been given a Value grade of D. ABBV sticks out from LLY in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABBV is the better option right now. Click to get this free report AbbVie Inc. (ABBV) : Fre... | AbbVie has a Zacks Rank of #2 (Buy), while Eli Lilly has a Zacks Rank of #3 (Hold) right now. These metrics, and several others, help ABBV earn a Value grade of B, while LLY has been given a Value grade of D. ABBV sticks out from LLY in both our Zacks Rank and Style Scores models, so value investors will likely feel th... |
22,037 | 2023-11-20 00:00:00 UTC | Drugmakers agree with UK govt on renewed revenue claw-back scheme | ABBV | https://www.nasdaq.com/articles/drugmakers-agree-with-uk-govt-on-renewed-revenue-claw-back-scheme | null | null | By Ludwig Burger
Nov 20 (Reuters) - The pharmaceutical industry has agreed terms with the British government to renew a medicines access scheme that requires drugmakers to pay part of their drug revenue to the government.
The Association of the British Pharmaceutical Industry (ABPI) said in a statement on Monday that t... | As a result, U.S. pharmaceutical majors AbbVie ABBV.N and Eli Lilly LLY.N in January withdrew from the scheme. By Ludwig Burger Nov 20 (Reuters) - The pharmaceutical industry has agreed terms with the British government to renew a medicines access scheme that requires drugmakers to pay part of their drug revenue to the... | As a result, U.S. pharmaceutical majors AbbVie ABBV.N and Eli Lilly LLY.N in January withdrew from the scheme. By Ludwig Burger Nov 20 (Reuters) - The pharmaceutical industry has agreed terms with the British government to renew a medicines access scheme that requires drugmakers to pay part of their drug revenue to the... | As a result, U.S. pharmaceutical majors AbbVie ABBV.N and Eli Lilly LLY.N in January withdrew from the scheme. By Ludwig Burger Nov 20 (Reuters) - The pharmaceutical industry has agreed terms with the British government to renew a medicines access scheme that requires drugmakers to pay part of their drug revenue to the... | As a result, U.S. pharmaceutical majors AbbVie ABBV.N and Eli Lilly LLY.N in January withdrew from the scheme. The Association of the British Pharmaceutical Industry (ABPI) said in a statement on Monday that the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) was newly agreed with the British g... |
22,038 | 2023-11-20 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-23 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,039 | 2023-11-16 00:00:00 UTC | Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-spdr-sp-dividend-etf-sdy-be-on-your-investing-radar-9 | null | null | The SPDR S&P Dividend ETF (SDY) was launched on 11/08/2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by State Street Global Advisors. It has amassed assets over $19.95 billion, making it one of the larg... | Looking at individual holdings, 3m Co W/d (MMM) accounts for about 2.83% of total assets, followed by Intl Business Machines Corp (IBM) and Abbvie Inc (ABBV). Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M... | Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M Company (MMM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000... | Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M Company (MMM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000... | Looking at individual holdings, 3m Co W/d (MMM) accounts for about 2.83% of total assets, followed by Intl Business Machines Corp (IBM) and Abbvie Inc (ABBV). Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M... |
22,040 | 2023-11-16 00:00:00 UTC | AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? | ABBV | https://www.nasdaq.com/articles/abbvie-and-pfizer-have-1-thing-in-common%3A-their-biggest-products-are-on-the-decline.-time | null | null | AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while Pfizer's coronavirus vaccine generated peak sales of $37 billion -- in 2022, in both cases. With results like those, you ... | AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while Pfizer's coronavirus vaccine generated peak sales of $37 billion -- in 2022, in both cases. Instead, AbbVie and Pfizer sh... | AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while Pfizer's coronavirus vaccine generated peak sales of $37 billion -- in 2022, in both cases. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. Instead, AbbVie and Pfizer sh... | AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while Pfizer's coronavirus vaccine generated peak sales of $37 billion -- in 2022, in both cases. AbbVie and the world's top-selling drug We'll start with AbbVie. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's t... | AbbVie and the world's top-selling drug We'll start with AbbVie. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while Pfizer's coronavirus vaccine generated peak sales of $37... |
22,041 | 2023-11-16 00:00:00 UTC | AbbVie Says Ubrelvy Reduced Development Of Headache If Given At Prodrome Phase Of Migraine Attack | ABBV | https://www.nasdaq.com/articles/abbvie-says-ubrelvy-reduced-development-of-headache-if-given-at-prodrome-phase-of-migraine | null | null | (RTTNews) - AbbVie (ABBV) Thursday said results from the Phase 3 PRODROME study showed that its approved drug Ubrelvy to treat migraine headaches, given during the prodrome phase of migraine attack, significantly reduced the likelihood of development of headache.
The prodrome is the earliest of four phases of a migrain... | (RTTNews) - AbbVie (ABBV) Thursday said results from the Phase 3 PRODROME study showed that its approved drug Ubrelvy to treat migraine headaches, given during the prodrome phase of migraine attack, significantly reduced the likelihood of development of headache. The prodrome is the earliest of four phases of a migrain... | (RTTNews) - AbbVie (ABBV) Thursday said results from the Phase 3 PRODROME study showed that its approved drug Ubrelvy to treat migraine headaches, given during the prodrome phase of migraine attack, significantly reduced the likelihood of development of headache. During the trial, patients with migraine who could ident... | (RTTNews) - AbbVie (ABBV) Thursday said results from the Phase 3 PRODROME study showed that its approved drug Ubrelvy to treat migraine headaches, given during the prodrome phase of migraine attack, significantly reduced the likelihood of development of headache. The prodrome is the earliest of four phases of a migrain... | (RTTNews) - AbbVie (ABBV) Thursday said results from the Phase 3 PRODROME study showed that its approved drug Ubrelvy to treat migraine headaches, given during the prodrome phase of migraine attack, significantly reduced the likelihood of development of headache. The prodrome is the earliest of four phases of a migrain... |
22,042 | 2023-11-15 00:00:00 UTC | iShares Russell 1000 Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-inflow-8 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $847.1 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 263,200,0... | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.5%, Costco Wholesale Corp (Symbol: COST) is up about 1.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.6%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed ... | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.5%, Costco Wholesale Corp (Symbol: COST) is up about 1.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.6%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year pr... | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.5%, Costco Wholesale Corp (Symbol: COST) is up about 1.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.5%, Costco Wholesale Corp (Symbol: COST) is up about 1.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... |
22,043 | 2023-11-15 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-9 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,044 | 2023-11-14 00:00:00 UTC | At $100 Does Merck Stock Have Room For Growth? | ABBV | https://www.nasdaq.com/articles/at-%24100-does-merck-stock-have-room-for-growth | null | null | Merck (NYSE: MRK) reported its Q3 results last month, with revenues and earnings beating the street estimates, and we believe that MRK stock has ample room for growth, as discussed below. The company reported revenue of $16.0 billion and adjusted profit of $2.13 per share compared to the consensus estimates of $15.3 bi... | In fact, consistently beating the S&P 500 – in good times and bad – has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. Given the current uncertain macroeconomic environment with high oi... | The company reported revenue of $16.0 billion and adjusted profit of $2.13 per share compared to the consensus estimates of $15.3 billion in sales and $1.96 earnings per share. For the full year 2023, the company raised its total revenue outlook to $59.7 billion and $60.2 billion versus the $58.6 billion to $59.6 billi... | Merck (NYSE: MRK) reported its Q3 results last month, with revenues and earnings beating the street estimates, and we believe that MRK stock has ample room for growth, as discussed below. For the full year 2023, the company raised its total revenue outlook to $59.7 billion and $60.2 billion versus the $58.6 billion to ... | The company reported revenue of $16.0 billion and adjusted profit of $2.13 per share compared to the consensus estimates of $15.3 billion in sales and $1.96 earnings per share. We estimate Merck’s Valuation to be $122 per share, reflecting about 20% upside from its current price of around $100. Total [2] MRK Return 0% ... |
22,045 | 2023-11-14 00:00:00 UTC | 7 Dividend Stocks Every Investor Should Own to Survive a Market Crash | ABBV | https://www.nasdaq.com/articles/7-dividend-stocks-every-investor-should-own-to-survive-a-market-crash | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
There are many ways to make money on Wall Street. One of the best proven strategies is buying and holding dividend stocks for long-term wealth creation.
Countless studies prove the superiority of income-generating stocks. The asset managers at Hartford Fund... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com It doesn’t look like AbbVie (NYSE:ABBV) would be a good choice for surviving a market crash. Yet AbbVie has about a dozen other drugs that generate over $1 billion annually along with a strong pipeline of therapies that should come to market eventually. The ma... | Costco (COST) Source: Shutterstock Even if AbbVie and Bank of America are rock-solid long-term investments, investors will appreciate Costco (NASDAQ:COST) showing superior gains in 2023. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com It doesn’t look like AbbVie (NYSE:ABBV) would be a good choice for surviv... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com It doesn’t look like AbbVie (NYSE:ABBV) would be a good choice for surviving a market crash. Yet AbbVie has about a dozen other drugs that generate over $1 billion annually along with a strong pipeline of therapies that should come to market eventually. The ma... | Costco (COST) Source: Shutterstock Even if AbbVie and Bank of America are rock-solid long-term investments, investors will appreciate Costco (NASDAQ:COST) showing superior gains in 2023. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com It doesn’t look like AbbVie (NYSE:ABBV) would be a good choice for surviv... |
22,046 | 2023-11-14 00:00:00 UTC | Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie | ABBV | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights-eli-lilly-novo-nordisk-jj-and-abbvie | null | null | For Immediate Release
Chicago, IL – November 14, 2023 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk NVO, J&J JNJ and AbbVie ABBV.
Industry: Big Pharma
Link: https://www.zacks.com/commentary/2183148/4-large-drug-stocks-likely-to-sail-through-industry-woes
The third-quarter earnings season has just... | For Immediate Release Chicago, IL – November 14, 2023 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk NVO, J&J JNJ and AbbVie ABBV. Among the large drugmakers, Eli Lilly, Novo Nordisk, J&J and AbbVie are worth retaining in your portfolio. AbbVie: The company has several new drugs in its portfolio w... | For Immediate Release Chicago, IL – November 14, 2023 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk NVO, J&J JNJ and AbbVie ABBV. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Fr... | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL ... | Though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025 with a high single-digit CAGR growth till the end of the decade. For Immediate Release Chicago, IL – November 14, 2023 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk NVO, J&J JNJ and AbbVie ABB... |
22,047 | 2023-11-14 00:00:00 UTC | 2 High-Yield Dividend Stocks You Can Buy Now and Hold for a Decade | ABBV | https://www.nasdaq.com/articles/2-high-yield-dividend-stocks-you-can-buy-now-and-hold-for-a-decade | null | null | There are no absolutely surefire ways to make big profits as an investor, but it's hard to do better than dividend-paying stocks. Businesses that commit to sharing a portion of their profits with their investors tend to outperform businesses that don't, and by a wide margin.
Over the 50-year period from 1973 through 20... | The stock has offered an unusually high dividend yield since the payout's inception in 2013 (shortly after AbbVie's spinoff from Abbott Labs) because investors have been nervous about the long-term sales prospects of its lead product, the blockbuster injectable anti-inflammatory drug Humira. AbbVie AbbVie (NYSE: ABBV) ... | AbbVie AbbVie (NYSE: ABBV) shares are down around 21% from the peak they hit in 2022. The stock has offered an unusually high dividend yield since the payout's inception in 2013 (shortly after AbbVie's spinoff from Abbott Labs) because investors have been nervous about the long-term sales prospects of its lead product,... | The stock has offered an unusually high dividend yield since the payout's inception in 2013 (shortly after AbbVie's spinoff from Abbott Labs) because investors have been nervous about the long-term sales prospects of its lead product, the blockbuster injectable anti-inflammatory drug Humira. AbbVie AbbVie (NYSE: ABBV) ... | AbbVie AbbVie (NYSE: ABBV) shares are down around 21% from the peak they hit in 2022. But AbbVie can offset the losses by growing its sales of newer drugs. AbbVie's dividend payout is currently set at just $6.20 annually. |
22,048 | 2023-11-14 00:00:00 UTC | 3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing | ABBV | https://www.nasdaq.com/articles/3-dividend-giants-to-grow-wealth-no-matter-what-the-market-is-doing | null | null | Growth stocks are known to stand out in bull markets, while stocks that are considered safer -- like a pharma company promising steady earnings -- generally excel in more difficult markets. It's a great idea to include a bit of both in your portfolio to support performance through any market environment. And there's on... | AbbVie AbbVie (NYSE: ABBV) saw the light of day in 2013 when it spun off from Abbott Laboratories. Right now, AbbVie pays an annual dividend of $6.20 at a yield of 4.47%, making it another dividend stock that tops the yield of the S&P 500. Today, AbbVie is proving it has what it takes to lift its dividend even through ... | AbbVie AbbVie (NYSE: ABBV) saw the light of day in 2013 when it spun off from Abbott Laboratories. Right now, AbbVie pays an annual dividend of $6.20 at a yield of 4.47%, making it another dividend stock that tops the yield of the S&P 500. Today, AbbVie is proving it has what it takes to lift its dividend even through ... | Right now, AbbVie pays an annual dividend of $6.20 at a yield of 4.47%, making it another dividend stock that tops the yield of the S&P 500. AbbVie AbbVie (NYSE: ABBV) saw the light of day in 2013 when it spun off from Abbott Laboratories. Today, AbbVie is proving it has what it takes to lift its dividend even through ... | Right now, AbbVie pays an annual dividend of $6.20 at a yield of 4.47%, making it another dividend stock that tops the yield of the S&P 500. AbbVie AbbVie (NYSE: ABBV) saw the light of day in 2013 when it spun off from Abbott Laboratories. Today, AbbVie is proving it has what it takes to lift its dividend even through ... |
22,049 | 2023-11-13 00:00:00 UTC | 4 Large Drug Stocks Likely to Sail Through Industry Woes | ABBV | https://www.nasdaq.com/articles/4-large-drug-stocks-likely-to-sail-through-industry-woes | null | null | The third-quarter earnings season has just concluded for the drug and biotech sector. The performance of the large drugmakers was rather lukewarm, with most posting mixed results.
Higher tax rates due to changes in global tax regulations, concerns around the economy and inflation, regular pipeline setbacks and the slo... | Among the large drugmakers, Eli Lilly LLY, Novo Nordisk NVO, J&J JNJ and AbbVie ABBV are worth retaining in your portfolio. Price and Consensus: JNJ AbbVie: The company has several new drugs in its portfolio with the potential to drive the top line and make up for lost revenues from its blockbuster medicine, Humira, wh... | Click to get this free report Eli Lilly and Company (LLY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Among the large drugmakers, Eli Li... | Click to get this free report Eli Lilly and Company (LLY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Among the large drugmakers, Eli Li... | Though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025 with a high single-digit CAGR growth till the end of the decade. Among the large drugmakers, Eli Lilly LLY, Novo Nordisk NVO, J&J JNJ and AbbVie ABBV are worth retaining in your portfolio. Price and Consensus: JNJ A... |
22,050 | 2023-11-13 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-21 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,051 | 2023-11-13 00:00:00 UTC | The Zacks Analyst Blog Highlights NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-nvidia-chevron-abbvie-alibaba-group-holding-and-morgan | null | null | For Immediate Release
Chicago, IL – November 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. NVDA, Chevro... | Stocks recently featured in the blog include: NVIDIA Corp. NVDA, Chevron Corp. CVX, AbbVie Inc. ABBV, Alibaba Group Holding Ltd. BABA and Morgan Stanley MS Here are highlights from Friday’s Analyst Blog: Top Research Reports for NVIDIA, Chevron and AbbVie The Zacks Research Daily presents the best research output of ou... | Stocks recently featured in the blog include: NVIDIA Corp. NVDA, Chevron Corp. CVX, AbbVie Inc. ABBV, Alibaba Group Holding Ltd. BABA and Morgan Stanley MS Here are highlights from Friday’s Analyst Blog: Top Research Reports for NVIDIA, Chevron and AbbVie The Zacks Research Daily presents the best research output of ou... | Stocks recently featured in the blog include: NVIDIA Corp. NVDA, Chevron Corp. CVX, AbbVie Inc. ABBV, Alibaba Group Holding Ltd. BABA and Morgan Stanley MS Here are highlights from Friday’s Analyst Blog: Top Research Reports for NVIDIA, Chevron and AbbVie The Zacks Research Daily presents the best research output of ou... | Stocks recently featured in the blog include: NVIDIA Corp. NVDA, Chevron Corp. CVX, AbbVie Inc. ABBV, Alibaba Group Holding Ltd. BABA and Morgan Stanley MS Here are highlights from Friday’s Analyst Blog: Top Research Reports for NVIDIA, Chevron and AbbVie The Zacks Research Daily presents the best research output of ou... |
22,052 | 2023-11-13 00:00:00 UTC | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | https://www.nasdaq.com/articles/investors-heavily-search-abbvie-inc.-abbv%3A-here-is-what-you-need-to-know-8 | null | null | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this drugmaker have returned -6.3% over the past month versus the Zacks S&P 500 composite's +1.4% change. The Zacks Large C... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie ... | Last Reported Results and Surprise History AbbVie reported revenues of $13.93 billion in the last reported quarter, representing a year-over-year change of -6%. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost... | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 2.3% over this period. AbbVie is expected to post earnings of $2.91 per share for the current quarter, representing a year-over-year change of -19.2%. | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 2.3% over this period. AbbVie is expected to post earnings of $2.91 per share for the current quarter, representing a year-over-year change of -19.2%. |
22,053 | 2023-11-10 00:00:00 UTC | AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock? | ABBV | https://www.nasdaq.com/articles/abbvies-%2421-billion-drug-humira-is-on-the-decline.-should-you-still-buy-this-dividend | null | null | For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought in almost $21 billion in annual sales, and the treatment helped AbbVie grow revenue and deliver dividend growth over time.... | For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. Today, trading at about 12 times forward earnings estimates, AbbVie looks like a bargain, considering its management of the Humira situation, progress on newer d... | After all, at its peak, Humira brought in almost $21 billion in annual sales, and the treatment helped AbbVie grow revenue and deliver dividend growth over time. Treating bipolar disorder and migraine Meanwhile, AbbVie's neuroscience drugs, Vraylar for bipolar disorder and Botox treatment for migraine, also are proving... | After all, at its peak, Humira brought in almost $21 billion in annual sales, and the treatment helped AbbVie grow revenue and deliver dividend growth over time. Treating bipolar disorder and migraine Meanwhile, AbbVie's neuroscience drugs, Vraylar for bipolar disorder and Botox treatment for migraine, also are proving... | After all, at its peak, Humira brought in almost $21 billion in annual sales, and the treatment helped AbbVie grow revenue and deliver dividend growth over time. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! For the past couple of years, ... |
22,054 | 2023-11-10 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-20 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,055 | 2023-11-10 00:00:00 UTC | Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises | ABBV | https://www.nasdaq.com/articles/ironwoods-irwd-q3-earnings-miss-mark-linzess-volume-rises | null | null | Ironwood Pharmaceuticals, Inc. IRWD reported adjusted earnings of 12 cents per share for third-quarter 2023, missing the Zacks Consensus Estimate of 17 cents. The company had reported adjusted earnings of 28 cents per share in the year-ago quarter.
Total revenues in the reported quarter were $113.7 million, beating the... | Image Source: Zacks Investment Research We note that in June 2023, ABBV received FDA approval for Linzess label expansion for treating functional constipation in pediatric patients aged 6-17 years. Quarter in Detail As reported by partner AbbVie Inc. ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — gene... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report MEI Pharma, Inc. (MEIP) : Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail As repo... | Quarter in Detail As reported by partner AbbVie Inc. ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $279 million in the United States, up 7% year over year, driven by prescription growth. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Iro... | Quarter in Detail As reported by partner AbbVie Inc. ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $279 million in the United States, up 7% year over year, driven by prescription growth. Ironwood and AbbVie equally share Linzess’ brand collaboration profits and losses. I... |
22,056 | 2023-11-10 00:00:00 UTC | Top Research Reports for NVIDIA, Chevron & AbbVie | ABBV | https://www.nasdaq.com/articles/top-research-reports-for-nvidia-chevron-abbvie | null | null | Friday, November 10, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie Inc. (ABBV). These research reports have been hand-picked from the... | Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie Inc. (ABBV). Shares of AbbVie have underperformed the Zacks Large Cap Pharmaceuticals industry over the past six months (-3.8% vs. +3.8%). Nonetheless, though revenues are e... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read NVIDIA (NVDA) Rides on Strong Adoption of GPUs, Partnerships Chevron (CVX) Gets Guyana Assets with Hess Buy AbbVie's (ABBV) Skyrizi, Rinvoq Key to Top-Line Growth Featured Reports Alibaba (BABA) Benefits F... | Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie Inc. (ABBV). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read NVIDIA (NVDA) Rides on Strong Adoption of GPU... | Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie Inc. (ABBV). Nonetheless, though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025. If you want an email notification each ti... |
22,057 | 2023-11-09 00:00:00 UTC | Deutsche Bank Initiates Coverage of Abbvie (ABBV) with Hold Recommendation | ABBV | https://www.nasdaq.com/articles/deutsche-bank-initiates-coverage-of-abbvie-abbv-with-hold-recommendation | null | null | Fintel reports that on November 9, 2023, Deutsche Bank initiated coverage of Abbvie (NYSE:ABBV) with a Hold recommendation.
Analyst Price Forecast Suggests 22.48% Upside
As of October 31, 2023, the average one-year price target for Abbvie is 173.95. The forecasts range from a low of 136.35 to a high of $215.25. The ave... | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Fintel reports that on November 9, 2023, Deutsche Bank initiated coverage of Abbvie (NYSE:ABBV) with a Hold recommendation. Analyst Price Forecast Suggests 22.48% Upsid... | Fintel reports that on November 9, 2023, Deutsche Bank initiated coverage of Abbvie (NYSE:ABBV) with a Hold recommendation. Analyst Price Forecast Suggests 22.48% Upside As of October 31, 2023, the average one-year price target for Abbvie is 173.95. The projected annual revenue for Abbvie is 55,229MM, an increase of 0.... | Abbvie Declares $1.48 Dividend On September 8, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on November 9, 2023, Deutsche Bank initiated coverage of Abbvie (NYSE:ABBV) with a Hold recommendation. Analyst Price Forecast Suggests 22.48% Upside As of Oct... | Fintel reports that on November 9, 2023, Deutsche Bank initiated coverage of Abbvie (NYSE:ABBV) with a Hold recommendation. Analyst Price Forecast Suggests 22.48% Upside As of October 31, 2023, the average one-year price target for Abbvie is 173.95. The projected annual revenue for Abbvie is 55,229MM, an increase of 0.... |
22,058 | 2023-11-08 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-8 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,059 | 2023-11-07 00:00:00 UTC | EXCLUSIVE-Activist investor Elliott targets drugmaker BioMarin -sources | ABBV | https://www.nasdaq.com/articles/exclusive-activist-investor-elliott-targets-drugmaker-biomarin-sources-0 | null | null | By Svea Herbst-Bayliss
NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical BMRN.O and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter.
The hedge fund, which oversees ... | Elliott also successfully pushed for drug makers Alexion Pharma AZN.L and Allergan ABBV.N to be sold. By Svea Herbst-Bayliss NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical BMRN.O and has been in discussions with the biotechnology company for mont... | Elliott also successfully pushed for drug makers Alexion Pharma AZN.L and Allergan ABBV.N to be sold. By Svea Herbst-Bayliss NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical BMRN.O and has been in discussions with the biotechnology company for mont... | Elliott also successfully pushed for drug makers Alexion Pharma AZN.L and Allergan ABBV.N to be sold. By Svea Herbst-Bayliss NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical BMRN.O and has been in discussions with the biotechnology company for mont... | Elliott also successfully pushed for drug makers Alexion Pharma AZN.L and Allergan ABBV.N to be sold. After the company last week lowered its 2023 guidance for Roctavian, some analysts cut sales forecasts for the coming years, even though they still see the drug hitting blockbuster status of $1 billion annually in the ... |
22,060 | 2023-11-07 00:00:00 UTC | EXCLUSIVE-Activist investor Elliott targets drugmaker BioMarin -sources | ABBV | https://www.nasdaq.com/articles/exclusive-activist-investor-elliott-targets-drugmaker-biomarin-sources | null | null | By Svea Herbst-Bayliss
NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical BMRN.O and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter.
The hedge fund, which oversees ... | Elliott also successfully pushed for drug makers Alexion Pharma AZN.L and Allergan ABBV.N to be sold. By Svea Herbst-Bayliss NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical BMRN.O and has been in discussions with the biotechnology company for mont... | Elliott also successfully pushed for drug makers Alexion Pharma AZN.L and Allergan ABBV.N to be sold. The share price fall has led some analysts to speculate about whether the company could become a takeover target. BioMarin said last week that Jean-Jacques Bienaime, 70, who has led the company since 2005, will be repl... | Elliott also successfully pushed for drug makers Alexion Pharma AZN.L and Allergan ABBV.N to be sold. By Svea Herbst-Bayliss NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical BMRN.O and has been in discussions with the biotechnology company for mont... | Elliott also successfully pushed for drug makers Alexion Pharma AZN.L and Allergan ABBV.N to be sold. After the company last week lowered its 2023 guidance for Roctavian, some analysts cut sales forecasts for the coming years, even though they still see the drug hitting blockbuster status of $1 billion annually in the ... |
22,061 | 2023-11-07 00:00:00 UTC | 3 Dividend Stocks That Are Perfect for Beginning Investors | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-are-perfect-for-beginning-investors | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While the meme trade phenomenon helped spark interest in the equities sector, passive-income providers generally offer a more solid foundation, thus warranting a closer look at dividend stocks for beginners. To be sure, these aren’t the sexiest ideas. But t... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Headquartered in North Chicago, Illinois, AbbVie (NYSE:ABBV) is one of the biggest pharmaceutical firms in the world. However, investors may soon appreciate AbbVie for its Allergan buyout. Admittedly, it’s a cynical argument but that also makes ABBV one of the dividen... | Moreover, analysts rate ABBV a moderate buy with a $169.67 price target, implying double-digit growth. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Headquartered in North Chicago, Illinois, AbbVie (NYSE:ABBV) is one of the biggest pharmaceutical firms in the world. However, investors may soon appreciate AbbVie f... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Headquartered in North Chicago, Illinois, AbbVie (NYSE:ABBV) is one of the biggest pharmaceutical firms in the world. However, investors may soon appreciate AbbVie for its Allergan buyout. Admittedly, it’s a cynical argument but that also makes ABBV one of the dividen... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Headquartered in North Chicago, Illinois, AbbVie (NYSE:ABBV) is one of the biggest pharmaceutical firms in the world. However, investors may soon appreciate AbbVie for its Allergan buyout. Admittedly, it’s a cynical argument but that also makes ABBV one of the dividen... |
22,062 | 2023-11-06 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-19 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,063 | 2023-11-06 00:00:00 UTC | Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-spdr-sp-dividend-etf-sdy-a-strong-etf-right-now-10 | null | null | Designed to provide broad exposure to the Style Box - Large Cap Value category of the market, the SPDR S&P Dividend ETF (SDY) is a smart beta exchange traded fund launched on 11/08/2005.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflect a specific... | Looking at individual holdings, 3m Co W/d (MMM) accounts for about 2.83% of total assets, followed by Intl Business Machines Corp (IBM) and Abbvie Inc (ABBV). Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M... | Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M Company (MMM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000... | Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M Company (MMM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000... | Looking at individual holdings, 3m Co W/d (MMM) accounts for about 2.83% of total assets, followed by Intl Business Machines Corp (IBM) and Abbvie Inc (ABBV). Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M... |
22,064 | 2023-11-06 00:00:00 UTC | Noteworthy ETF Inflows: VONG, ABBV, PEP, CRM | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vong-abbv-pep-crm | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 Growth ETF (Symbol: VONG) where we have detected an approximate $595.0 million dollar inflow -- that's a 4.3% increase week over week in outstanding units (from 197,131... | Among the largest underlying components of VONG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, PepsiCo Inc (Symbol: PEP) is up about 0.1%, and Salesforce Inc (Symbol: CRM) is lower by about 0.8%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accomm... | Among the largest underlying components of VONG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, PepsiCo Inc (Symbol: PEP) is up about 0.1%, and Salesforce Inc (Symbol: CRM) is lower by about 0.8%. For a complete list of holdings, visit the VONG Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of VONG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, PepsiCo Inc (Symbol: PEP) is up about 0.1%, and Salesforce Inc (Symbol: CRM) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of VONG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, PepsiCo Inc (Symbol: PEP) is up about 0.1%, and Salesforce Inc (Symbol: CRM) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
22,065 | 2023-11-05 00:00:00 UTC | 3 Spectacular High-Yield Dividend Stocks to Buy in November | ABBV | https://www.nasdaq.com/articles/3-spectacular-high-yield-dividend-stocks-to-buy-in-november | null | null | Not all dividend stocks are in the same league. Some offer puny yields. Others, though, provide exceptionally high ones plus solid long-term growth prospects.
Three Motley Fool contributors think they've identified stocks that belong squarely in the latter group. Here's why they view drugmakers AbbVie (NYSE: ABBV), Nov... | CEO Rick Gonzalez even noted in the company's Q3earnings callthat the double-digit revenue growth for AbbVie's products, excluding Humira, represented "a considerable acceleration from the first half of the year." Here's why they view drugmakers AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) as spect... | Here's why they view drugmakers AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) as spectacular high-yield dividend stocks to buy in November. Raring for a rebound Keith Speights (AbbVie): You might wonder whether "spectacular" is an adjective that should be used with AbbVie after a brief glance at its... | Here's why they view drugmakers AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) as spectacular high-yield dividend stocks to buy in November. Raring for a rebound Keith Speights (AbbVie): You might wonder whether "spectacular" is an adjective that should be used with AbbVie after a brief glance at its... | AbbVie's dividend yield stands at nearly 4.4%. Here's why they view drugmakers AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) as spectacular high-yield dividend stocks to buy in November. Raring for a rebound Keith Speights (AbbVie): You might wonder whether "spectacular" is an adjective that should ... |
22,066 | 2023-11-04 00:00:00 UTC | ABBV Quantitative Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-quantitative-stock-analysis-7 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,067 | 2023-11-03 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-126 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | AbbVie Inc (Symbol: ABBV) $143.26 $173.27 20.95% RLI Corp (Symbol: RLI) $134.35 $158.75 18.16% Sherwin-Williams Co (Symbol: SHW) $245.32 $289.56 18.03% NIKE Inc (Symbol: NKE) $105.08 $123.65 17.67% Automatic Data Processing Inc. (Symbol: ADP) $218.56 $250.57 14.65% The average 12-month analyst targets are only targets ... | AbbVie Inc (Symbol: ABBV) $143.26 $173.27 20.95% RLI Corp (Symbol: RLI) $134.35 $158.75 18.16% Sherwin-Williams Co (Symbol: SHW) $245.32 $289.56 18.03% NIKE Inc (Symbol: NKE) $105.08 $123.65 17.67% Automatic Data Processing Inc. (Symbol: ADP) $218.56 $250.57 14.65% The average 12-month analyst targets are only targets ... | AbbVie Inc (Symbol: ABBV) $143.26 $173.27 20.95% RLI Corp (Symbol: RLI) $134.35 $158.75 18.16% Sherwin-Williams Co (Symbol: SHW) $245.32 $289.56 18.03% NIKE Inc (Symbol: NKE) $105.08 $123.65 17.67% Automatic Data Processing Inc. (Symbol: ADP) $218.56 $250.57 14.65% The average 12-month analyst targets are only targets ... | AbbVie Inc (Symbol: ABBV) $143.26 $173.27 20.95% RLI Corp (Symbol: RLI) $134.35 $158.75 18.16% Sherwin-Williams Co (Symbol: SHW) $245.32 $289.56 18.03% NIKE Inc (Symbol: NKE) $105.08 $123.65 17.67% Automatic Data Processing Inc. (Symbol: ADP) $218.56 $250.57 14.65% The average 12-month analyst targets are only targets ... |
22,068 | 2023-11-03 00:00:00 UTC | Is AbbVie Stock a Buy Now? | ABBV | https://www.nasdaq.com/articles/is-abbvie-stock-a-buy-now-3 | null | null | With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why now might not seem like a good time to buy AbbVie (NYSE: ABBV) stock. To make matters worse, its share prices are down by more than 9% this year so far, badly underperforming the market. Despite the... | With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why now might not seem like a good time to buy AbbVie (NYSE: ABBV) stock. Does this potential for improvement make AbbVie stock a buy right now, given that its turnaround clearly hasn't started yet? Let... | As CMS will now be free to negotiate and therefore lower the selling price of Imbruvica, AbbVie expects to make less money on it in the future (which is reflected in its finances as the impairment). With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why... | With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why now might not seem like a good time to buy AbbVie (NYSE: ABBV) stock. Does this potential for improvement make AbbVie stock a buy right now, given that its turnaround clearly hasn't started yet? Let... | As CMS will now be free to negotiate and therefore lower the selling price of Imbruvica, AbbVie expects to make less money on it in the future (which is reflected in its finances as the impairment). With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why... |
22,069 | 2023-11-02 00:00:00 UTC | Cigna raises 2023 profit forecast on lower medical costs | ABBV | https://www.nasdaq.com/articles/cigna-raises-2023-profit-forecast-on-lower-medical-costs-0 | null | null | By Khushi Mandowara
Nov 2 (Reuters) - The Cigna Group CI.N raised its full-year profit forecast on Thursday, banking on strength in its pharmacy benefit unit and lower-than-expected insurance claims, sending the company's shares up 1.2%.
Health insurers had warned of a jump in medical costs earlier this year as older a... | Biosimilar growth at the Evernoth unit even next year will largely be driven by close copies of AbbVie's ABBV.N arthritis treatment Humira, Evanko said. By Khushi Mandowara Nov 2 (Reuters) - The Cigna Group CI.N raised its full-year profit forecast on Thursday, banking on strength in its pharmacy benefit unit and lower... | Biosimilar growth at the Evernoth unit even next year will largely be driven by close copies of AbbVie's ABBV.N arthritis treatment Humira, Evanko said. Revenue from the company's health insurance unit rose 14% to $12.77 billion in the quarter as memberships in its commercial plans, which usually have a higher premium,... | Biosimilar growth at the Evernoth unit even next year will largely be driven by close copies of AbbVie's ABBV.N arthritis treatment Humira, Evanko said. By Khushi Mandowara Nov 2 (Reuters) - The Cigna Group CI.N raised its full-year profit forecast on Thursday, banking on strength in its pharmacy benefit unit and lower... | Biosimilar growth at the Evernoth unit even next year will largely be driven by close copies of AbbVie's ABBV.N arthritis treatment Humira, Evanko said. By Khushi Mandowara Nov 2 (Reuters) - The Cigna Group CI.N raised its full-year profit forecast on Thursday, banking on strength in its pharmacy benefit unit and lower... |
22,070 | 2023-11-02 00:00:00 UTC | These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | ABBV | https://www.nasdaq.com/articles/these-2-medical-stocks-could-beat-earnings%3A-why-they-should-be-on-your-radar-5 | null | null | Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.
We know earnings results are vital, but how a company performs compared to bottom line expectations c... | AZN and ABBV's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report. Another solid-looking stock is AbbVie (ABBV). AbbVie, which is readying to report earnings on February 8, 2024, sits at a Zacks Rank #3 (Hold) right now. | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Another solid-looking stock is AbbVie (ABBV). AbbVie, which is readying to report earnings on February 8, 2024, sits at a Zacks Rank #3 (Hold) ri... | Another solid-looking stock is AbbVie (ABBV). AbbVie, which is readying to report earnings on February 8, 2024, sits at a Zacks Rank #3 (Hold) right now. It's Most Accurate Estimate is currently $2.93 a share, and ABBV is 98 days out from its next earnings report. | AZN and ABBV's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report. Another solid-looking stock is AbbVie (ABBV). AbbVie, which is readying to report earnings on February 8, 2024, sits at a Zacks Rank #3 (Hold) right now. |
22,071 | 2023-11-02 00:00:00 UTC | Analysts See 17% Gains Ahead For HDV | ABBV | https://www.nasdaq.com/articles/analysts-see-17-gains-ahead-for-hdv | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core High Dividend ETF ... | Below is a twelve month price history chart comparing the stock performance of ABBV, CLX, and PNM: Combined, ABBV, CLX, and PNM represent 6.37% of the iShares Core High Dividend ETF. Three of HDV's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Clorox Co (Symbol: C... | Three of HDV's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Clorox Co (Symbol: CLX), and PNM Resources Inc (Symbol: PNM). Below is a twelve month price history chart comparing the stock performance of ABBV, CLX, and PNM: Combined, ABBV, CLX, and PNM represent 6.3... | Three of HDV's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Clorox Co (Symbol: CLX), and PNM Resources Inc (Symbol: PNM). Although ABBV has traded at a recent price of $142.47/share, the average analyst target is 21.62% higher at $173.27/share. Below is a twelve ... | Although ABBV has traded at a recent price of $142.47/share, the average analyst target is 21.62% higher at $173.27/share. Three of HDV's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Clorox Co (Symbol: CLX), and PNM Resources Inc (Symbol: PNM). Below is a twelve ... |
22,072 | 2023-11-02 00:00:00 UTC | December 22nd Options Now Available For AbbVie | ABBV | https://www.nasdaq.com/articles/december-22nd-options-now-available-for-abbvie | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the December 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new December 22nd contracts and identified one put and one call contract of particular interest.
The put... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $144.00 strike highlighted in red: Considering the fact that the $144.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $142.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $144.00 strike price has a current bid of $3.65. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new December 22nd contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $144.00 strike highlighted in red: Consi... |
22,073 | 2023-11-02 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-49 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,074 | 2023-11-02 00:00:00 UTC | 3 Dividend Stocks That Are Investor Safe Havens | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-are-investor-safe-havens | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
DividendChannel.com has a list of 25 SAFE dividend stocks.
By the site’s definition, these stocks have a reasonably high yield; the quarterly dividend is accelerating, they’ve never missed or lowered dividends and they have paid dividends for at least 20 y... | AbbVie (ABBV) AbbVie (NYSE:ABBV) hasn’t paid dividends for as long as either NextEra or Aflac — it was spun off from Abbott Laboratories (NYSE:ABT) in 2012. My colleague felt the lowering of the distribution at the Florida utility’s subsidiary NextEra Energy Partners (NYSE:NEP) was an emphatic signal to sell NEE shares... | AbbVie (ABBV) AbbVie (NYSE:ABBV) hasn’t paid dividends for as long as either NextEra or Aflac — it was spun off from Abbott Laboratories (NYSE:ABT) in 2012. InvestorPlace - Stock Market News, Stock Advice & Trading Tips DividendChannel.com has a list of 25 SAFE dividend stocks. NextEra Energy (NEE) Source: IgorGolovnio... | AbbVie (ABBV) AbbVie (NYSE:ABBV) hasn’t paid dividends for as long as either NextEra or Aflac — it was spun off from Abbott Laboratories (NYSE:ABT) in 2012. By the site’s definition, these stocks have a reasonably high yield; the quarterly dividend is accelerating, they’ve never missed or lowered dividends and they hav... | AbbVie (ABBV) AbbVie (NYSE:ABBV) hasn’t paid dividends for as long as either NextEra or Aflac — it was spun off from Abbott Laboratories (NYSE:ABT) in 2012. By the site’s definition, these stocks have a reasonably high yield; the quarterly dividend is accelerating, they’ve never missed or lowered dividends and they hav... |
22,075 | 2023-11-01 00:00:00 UTC | Pfizer Posted a Steep Loss. Is It Time to Sell? | ABBV | https://www.nasdaq.com/articles/pfizer-posted-a-steep-loss.-is-it-time-to-sell | null | null | It's been about a couple of weeks since Pfizer (NYSE: PFE) promised to make Halloween extra spooky by warning us that third-quarter results would be disappointing.
It turns out the warning was more than justified. Instead of the large profit investors have gotten used to, Pfizer reported a third-quarter loss of about $... | This allows pharmacies to dispense Pfizer's low-cost biosimilar version even if their doctor prescribes Humira, a drug that racked up $18.6 billion in U.S. sales for AbbVie (NYSE: ABBV) last year. It's been about a couple of weeks since Pfizer (NYSE: PFE) promised to make Halloween extra spooky by warning us that third... | This allows pharmacies to dispense Pfizer's low-cost biosimilar version even if their doctor prescribes Humira, a drug that racked up $18.6 billion in U.S. sales for AbbVie (NYSE: ABBV) last year. Non-COVID sales are rising Paxlovid sales fell hard, but the rest of Pfizer's product line is quickly picking up the slack.... | This allows pharmacies to dispense Pfizer's low-cost biosimilar version even if their doctor prescribes Humira, a drug that racked up $18.6 billion in U.S. sales for AbbVie (NYSE: ABBV) last year. Pfizer expects non-COVID revenue to rise 6% to 8% in 2023, plus a slate of new drug launches could make the next few years ... | This allows pharmacies to dispense Pfizer's low-cost biosimilar version even if their doctor prescribes Humira, a drug that racked up $18.6 billion in U.S. sales for AbbVie (NYSE: ABBV) last year. Pfizer expects non-COVID revenue to rise 6% to 8% in 2023, plus a slate of new drug launches could make the next few years ... |
22,076 | 2023-11-01 00:00:00 UTC | Investor patience tested as pharmaceutical stocks take a tumble | ABBV | https://www.nasdaq.com/articles/investor-patience-tested-as-pharmaceutical-stocks-take-a-tumble | null | null | The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.
S&P 500 components Bristol Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Merck & Co., Inc. (NYSE: MRK... | S&P 500 components Bristol Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) are all trading well off their previous highs. That acquisition may have played a role in the stock's selloff on October 31, as investors fretted th... | S&P 500 components Bristol Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) are all trading well off their previous highs. The latest round of pharmaceutical stock earnings isn't helping sector performance. Eli Lilly forecas... | S&P 500 components Bristol Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) are all trading well off their previous highs. That acquisition may have played a role in the stock's selloff on October 31, as investors fretted th... | S&P 500 components Bristol Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) are all trading well off their previous highs. The company also increased its revenue forecast. Amgen stock is up 11.35% in the past three months. |
22,077 | 2023-11-01 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, Exxon Mobil, Kontoor Brands, Select Water Solutions and Macatawa Bank | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-exxon-mobil-kontoor-brands-select-water-solutions | null | null | For Immediate Release
Chicago, IL – November 1, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Exxon Mo... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, Exxon Mobil Corp. XOM, Kontoor Brands, Inc. KTB, Select Water Solutions, Inc. WTTR and Macatawa Bank Corp. MCBC. Five such stocks are AbbVie Inc., Exxon Mobil Corp., Kontoor Brands, Inc., Select Water Solutions, Inc. and Macatawa Bank Corp.. AbbVie Inc. ha... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, Exxon Mobil Corp. XOM, Kontoor Brands, Inc. KTB, Select Water Solutions, Inc. WTTR and Macatawa Bank Corp. MCBC. Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Select... | Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Select Water Solutions, Inc. (WTTR) : Free Stock Analysis Report Macatawa Bank Corporation (MCBC) : Free Stock Analysis Report Kontoor Brands, Inc. (KTB) : Free Stock Analysis Report ... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, Exxon Mobil Corp. XOM, Kontoor Brands, Inc. KTB, Select Water Solutions, Inc. WTTR and Macatawa Bank Corp. MCBC. ABBV has a dividend yield of 4.26%. Five such stocks are AbbVie Inc., Exxon Mobil Corp., Kontoor Brands, Inc., Select Water Solutions, Inc. and... |
22,078 | 2023-10-31 00:00:00 UTC | Amgen third-quarter sales rise 5%, profit up before charge | ABBV | https://www.nasdaq.com/articles/amgen-third-quarter-sales-rise-5-profit-up-before-charge-0 | null | null | By Deena Beasley
Oct 31 (Reuters) - Amgen AMGN.O, which earlier this month acquired Horizon Therapeutics for $27.8 billion, said on Tuesday its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.
Amgen said it would discuss sales of Horizon's drugs on a conference call with ana... | Sales of Amjevita, Amgen's new biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, rose 30% to $152 million, but sales of cancer drug Lumakras fell 31% to $52 million and sales of arthritis drug Enbrel fell 6% to $1.1 billion. By Deena Beasley Oct 31 (Reuters) - Amgen AMGN.O, which earlier this mon... | Sales of Amjevita, Amgen's new biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, rose 30% to $152 million, but sales of cancer drug Lumakras fell 31% to $52 million and sales of arthritis drug Enbrel fell 6% to $1.1 billion. Amgen said it would discuss sales of Horizon's drugs on a conference cal... | Sales of Amjevita, Amgen's new biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, rose 30% to $152 million, but sales of cancer drug Lumakras fell 31% to $52 million and sales of arthritis drug Enbrel fell 6% to $1.1 billion. Amgen said it would discuss sales of Horizon's drugs on a conference cal... | Sales of Amjevita, Amgen's new biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, rose 30% to $152 million, but sales of cancer drug Lumakras fell 31% to $52 million and sales of arthritis drug Enbrel fell 6% to $1.1 billion. Amgen said it would discuss sales of Horizon's drugs on a conference cal... |
22,079 | 2023-10-31 00:00:00 UTC | Is AbbVie Still a Good Dividend Stock to Buy? | ABBV | https://www.nasdaq.com/articles/is-abbvie-still-a-good-dividend-stock-to-buy-0 | null | null | One thing income seekers don't want to see from the businesses they invest in is a major disruption to their incoming cash flows. Unfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S. earlier this year.
U.S. Humira sales ... | Unfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S. earlier this year. Its loss of exclusivity is creating a mighty big hole to fill, but there are some powerful new growth drivers in AbbVie's product portfolio. Let's m... | Its loss of exclusivity is creating a mighty big hole to fill, but there are some powerful new growth drivers in AbbVie's product portfolio. About the dividend AbbVie's third-quarter earnings announcement came with a modest 4.7% dividend raise. Unfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-... | Humira's decline is upsetting to watch, but we can be fairly confident about AbbVie's ability to offset those losses and return to growth in a few short years. Unfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S. earlier... | Unfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S. earlier this year. Its loss of exclusivity is creating a mighty big hole to fill, but there are some powerful new growth drivers in AbbVie's product portfolio. Let's m... |
22,080 | 2023-10-31 00:00:00 UTC | 5 Solid Stocks to Watch That Recently Hiked Dividends | ABBV | https://www.nasdaq.com/articles/5-solid-stocks-to-watch-that-recently-hiked-dividends | null | null | Wall Street has remained volatile over the past couple of months owing to multiple domestic and geopolitical reasons. Rising bond yield and lack of clarity over the Federal Reserve’s future course of action with its interest rate hikes have been taking a toll on stocks.
The Federal Reserve kept its benchmark policy rat... | The deal has transformed ABBV's portfolio by lowering its dependence on Humira, its flagship product, which has lost patent protection in Europe as well as the United States. Five such stocks are AbbVie Inc. ABBV, Exxon Mobil Corporation XOM, Kontoor Brands, Inc. KTB, Select Water Solutions, Inc. WTTR and Macatawa Bank... | Five such stocks are AbbVie Inc. ABBV, Exxon Mobil Corporation XOM, Kontoor Brands, Inc. KTB, Select Water Solutions, Inc. WTTR and Macatawa Bank Corporation MCBC. Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Select Water Soluti... | Five such stocks are AbbVie Inc. ABBV, Exxon Mobil Corporation XOM, Kontoor Brands, Inc. KTB, Select Water Solutions, Inc. WTTR and Macatawa Bank Corporation MCBC. Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Select Water Soluti... | Five such stocks are AbbVie Inc. ABBV, Exxon Mobil Corporation XOM, Kontoor Brands, Inc. KTB, Select Water Solutions, Inc. WTTR and Macatawa Bank Corporation MCBC. ABBV has a dividend yield of 4.26%. AbbVie Inc. has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock d... |
22,081 | 2023-10-31 00:00:00 UTC | Amgen third-quarter sales rise 5%; profit up before charge | ABBV | https://www.nasdaq.com/articles/amgen-third-quarter-sales-rise-5-profit-up-before-charge | null | null | By Deena Beasley
Oct 31 (Reuters) - Amgen AMGN.O, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.
Amgen said it would discuss sales of Horizon's drugs on a conference call with ana... | Sales of Amjevita, Amgen's new biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, rose 30% to $152 million, but sales of cancer drug Lumakras fell 31% to $52 million and sales of arthritis drug Enbrel fell 6% to $1.1 billion. By Deena Beasley Oct 31 (Reuters) - Amgen AMGN.O, which earlier this mon... | Sales of Amjevita, Amgen's new biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, rose 30% to $152 million, but sales of cancer drug Lumakras fell 31% to $52 million and sales of arthritis drug Enbrel fell 6% to $1.1 billion. Excluding a $650 million charge for discontinuing experimental prostate ... | Sales of Amjevita, Amgen's new biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, rose 30% to $152 million, but sales of cancer drug Lumakras fell 31% to $52 million and sales of arthritis drug Enbrel fell 6% to $1.1 billion. Amgen said it would discuss sales of Horizon's drugs on a conference cal... | Sales of Amjevita, Amgen's new biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, rose 30% to $152 million, but sales of cancer drug Lumakras fell 31% to $52 million and sales of arthritis drug Enbrel fell 6% to $1.1 billion. Amgen said it would discuss sales of Horizon's drugs on a conference cal... |
22,082 | 2023-10-31 00:00:00 UTC | J&J stock down as business unit mulls talc-related bankruptcy | ABBV | https://www.nasdaq.com/articles/jj-stock-down-as-business-unit-mulls-talc-related-bankruptcy | null | null | Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder.
Financially, a bankruptcy for that unit would make sense, so the company could avoid substantial payouts that could put a d... | Imbruvica, which is co-marketed by AbbVie Inc. (NYSE: ABBV), is subject to Medicare price negotiations. Financially, a bankruptcy for that unit would make sense, so the company could avoid substantial payouts that could put a dent in earnings. At least 18 jury trials are in the works in the coming year, spurring J&J to... | Imbruvica, which is co-marketed by AbbVie Inc. (NYSE: ABBV), is subject to Medicare price negotiations. No longer selling talc baby powder In response to lawsuits and bad publicity surrounding the products, Johnson & Johnson said in May 2020 it would stop selling talc-based baby powder in the U.S. and Canada. Boosted f... | Imbruvica, which is co-marketed by AbbVie Inc. (NYSE: ABBV), is subject to Medicare price negotiations. Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder. No longer selling ta... | Imbruvica, which is co-marketed by AbbVie Inc. (NYSE: ABBV), is subject to Medicare price negotiations. There have already been two previous bankruptcy filings by the LTL Management unit, although those cases were dismissed. Those products are now sold by Johnson & Johnson spinoff Kenvue Inc. (NYSE: KVUE). |
22,083 | 2023-10-31 00:00:00 UTC | Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View | ABBV | https://www.nasdaq.com/articles/amgen-amgn-beats-on-q3-earnings-beat-lags-sales-ups-view | null | null | Amgen AMGN reported third-quarter 2023 adjusted earnings of $4.96 per share, which beat the Zacks Consensus Estimate of $4.65. Earnings rose 6% year over year due to higher revenues, which were partially offset by higher operating costs.
Total revenues of $6.90 billion missed the Zacks Consensus Estimate of $6.96 billi... | Amjevita/Amgevita (a biosimilar of AbbVie’s [ABBV] Humira) sales were $152 million in the quarter, up 30% year over year, driven by volume growth. Amgen launched Amjevita in the United States at a 55% lower list price than the current price set by AbbVie for Humira in February. Also, several more biosimilar versions of... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Amjevita/Amgevita (a biosi... | Amjevita/Amgevita (a biosimilar of AbbVie’s [ABBV] Humira) sales were $152 million in the quarter, up 30% year over year, driven by volume growth. Amgen launched Amjevita in the United States at a 55% lower list price than the current price set by AbbVie for Humira in February. Also, several more biosimilar versions of... | Amjevita/Amgevita (a biosimilar of AbbVie’s [ABBV] Humira) sales were $152 million in the quarter, up 30% year over year, driven by volume growth. Amgen launched Amjevita in the United States at a 55% lower list price than the current price set by AbbVie for Humira in February. Also, several more biosimilar versions of... |
22,084 | 2023-10-31 00:00:00 UTC | ABBV Quantitative Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-quantitative-stock-analysis-6 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,085 | 2023-10-31 00:00:00 UTC | Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors | ABBV | https://www.nasdaq.com/articles/pfizers-coming-for-abbvies-market-share.-heres-what-it-means-for-investors | null | null | On Oct. 13, regulators at the Food and Drug Administration (FDA) ruled that Pfizer's (NYSE: PFE) new drug for moderate to severe ulcerative colitis (UC), Velsipity, was ready for prime time. That puts the company on a collision course with AbbVie (NYSE: ABBV), the leader of the market for ulcerative colitis therapies f... | So Velsipity and Litfulo will be nibbling on AbbVie's market share in multiple segments where it's looking for growth through the rest of the decade, assuming it can get regulatory approval for the additional indications after the relevant clinical trials are done. Still, the probability of AbbVie hitting revenue headw... | That puts the company on a collision course with AbbVie (NYSE: ABBV), the leader of the market for ulcerative colitis therapies for many years. In a worst-case scenario, it's possible that AbbVie might get its lunch eaten. Wall Street analysts anticipate that in fiscal 2024, Pfizer will bring in $64 billion of revenue ... | Wall Street analysts anticipate that in fiscal 2024, Pfizer will bring in $64 billion of revenue and AbbVie will bring in $53 billion -- and so capturing a decent share of that market could easily drive significant growth. But UC isn't the only market where Pfizer and AbbVie are expected to do battle over the coming ye... | That puts the company on a collision course with AbbVie (NYSE: ABBV), the leader of the market for ulcerative colitis therapies for many years. But UC isn't the only market where Pfizer and AbbVie are expected to do battle over the coming years. In a worst-case scenario, it's possible that AbbVie might get its lunch ea... |
22,086 | 2023-10-30 00:00:00 UTC | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar-8 | null | null | Launched on 03/09/2006, the First Trust Morningstar Dividend Leaders ETF (FDL) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by First Trust Advisors. It has amassed assets over $3.79 billion, making it one o... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 8.68% of total assets, followed by Chevron Corporation (CVX) and Verizon Communications Inc. (VZ). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis ... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 8.68% of total assets, followed by Chevron Corporation (CVX) and Verizon Communications Inc. (VZ). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis ... | Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Verizon Communications Inc. (VZ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports Vangu... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 8.68% of total assets, followed by Chevron Corporation (CVX) and Verizon Communications Inc. (VZ). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis ... |
22,087 | 2023-10-30 00:00:00 UTC | Why AbbVie Stock Was a Winner on Monday | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-was-a-winner-on-monday | null | null | Pharmaceutical company AbbVie (NYSE: ABBV) was a cure for the investor blues on Monday. Shares of the company rose more than 2% in price on an analyst's recommendation upgrade. AbbVie stock's resulting pop topped the bellwether S&P 500 index, which managed a comparatively light 1.2% increase on the day.
Barclays upgrad... | AbbVie stock's resulting pop topped the bellwether S&P 500 index, which managed a comparatively light 1.2% increase on the day. Prognosticator feels that the sell-off was not reasonable Gould's foundational argument, which certainly has merit given the strength of AbbVie's portfolio and its well-stuffed pipeline, is th... | AbbVie stock's resulting pop topped the bellwether S&P 500 index, which managed a comparatively light 1.2% increase on the day. Barclays upgraded its recommendation to buy That analyst was Barclays' Carter Gould, who, before market open, pushed up his AbbVie recommendation one peg to overweight (read: buy) from his pre... | Barclays upgraded its recommendation to buy That analyst was Barclays' Carter Gould, who, before market open, pushed up his AbbVie recommendation one peg to overweight (read: buy) from his previous tag of equalweight (hold). 10 stocks we like better than AbbVie When our analyst team has a stock tip, it can pay to liste... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Pharmaceutical company AbbVie (NYSE: ABBV) was a cure for the investor blues on Monday. AbbVie stock's resulting pop topped the bellwether S&P 500 index, which managed a comparatively light 1.... |
22,088 | 2023-10-30 00:00:00 UTC | Morgan Stanley Maintains Abbvie (ABBV) Overweight Recommendation | ABBV | https://www.nasdaq.com/articles/morgan-stanley-maintains-abbvie-abbv-overweight-recommendation-2 | null | null | Fintel reports that on October 30, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 24.75% Upside
As of October 5, 2023, the average one-year price target for Abbvie is 173.32. The forecasts range from a low of 136.35 to a high of $215.25. ... | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Fintel reports that on October 30, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 24.7... | Fintel reports that on October 30, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 24.75% Upside As of October 5, 2023, the average one-year price target for Abbvie is 173.32. The projected annual revenue for Abbvie is 55,229MM, an increas... | Abbvie Declares $1.48 Dividend On September 8, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on October 30, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 24.75% Upside A... | Fintel reports that on October 30, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 24.75% Upside As of October 5, 2023, the average one-year price target for Abbvie is 173.32. The projected annual revenue for Abbvie is 55,229MM, an increas... |
22,089 | 2023-10-30 00:00:00 UTC | 2 No-Brainer Dividend Stocks to Buy This Week | ABBV | https://www.nasdaq.com/articles/2-no-brainer-dividend-stocks-to-buy-this-week | null | null | Dividend stocks can be consistent market-beaters. However, empirical research shows that the best dividend stocks tend to generate better-than-average returns because of their underlying value proposition -- not their potential to deliver consistent levels of passive income.
Which undervalued dividend stocks are worth ... | Although AbbVie may have to unearth a hidden gem on the merger-and-acquisition scene to shore up its long-term financial projection, the company's top-shelf management team arguably deserves the benefit of the doubt on this matter. Following the latest round of corporate earnings, AbbVie (NYSE: ABBV) and Altria (NYSE: ... | Following the latest round of corporate earnings, AbbVie (NYSE: ABBV) and Altria (NYSE: MO) both come across as highly attractive buys as a result of their hefty yields and core value propositions. Although AbbVie may have to unearth a hidden gem on the merger-and-acquisition scene to shore up its long-term financial p... | So with AbbVie's stock trading a paltry 12.8 times projected earnings, it might be a good idea to start to build a position in this Dividend King or add to an already existing position. Following the latest round of corporate earnings, AbbVie (NYSE: ABBV) and Altria (NYSE: MO) both come across as highly attractive buys... | Altria: A 9.93% yield Like AbbVie, American tobacco giant Altria hasn't been a winner for shareholders in 2023. Following the latest round of corporate earnings, AbbVie (NYSE: ABBV) and Altria (NYSE: MO) both come across as highly attractive buys as a result of their hefty yields and core value propositions. AbbVie: A ... |
22,090 | 2023-10-30 00:00:00 UTC | S&P 500 Movers: RVTY, WDC | ABBV | https://www.nasdaq.com/articles/sp-500-movers%3A-rvty-wdc | null | null | In early trading on Monday, shares of Western Digital topped the list of the day's best performing components of the S&P 500 index, trading up 10.3%. Year to date, Western Digital registers a 36.2% gain.
And the worst performing S&P 500 component thus far on the day is Revvity trading down 17.0%. Revvity is lower by ab... | Two other components making moves today are ON Semiconductor, trading down 15.4%, and AbbVie, trading up 3.8% on the day. Year to date, Western Digital registers a 36.2% gain. And the worst performing S&P 500 component thus far on the day is Revvity trading down 17.0%. | Two other components making moves today are ON Semiconductor, trading down 15.4%, and AbbVie, trading up 3.8% on the day. In early trading on Monday, shares of Western Digital topped the list of the day's best performing components of the S&P 500 index, trading up 10.3%. Year to date, Western Digital registers a 36.2% ... | Two other components making moves today are ON Semiconductor, trading down 15.4%, and AbbVie, trading up 3.8% on the day. In early trading on Monday, shares of Western Digital topped the list of the day's best performing components of the S&P 500 index, trading up 10.3%. And the worst performing S&P 500 component thus ... | Two other components making moves today are ON Semiconductor, trading down 15.4%, and AbbVie, trading up 3.8% on the day. In early trading on Monday, shares of Western Digital topped the list of the day's best performing components of the S&P 500 index, trading up 10.3%. And the worst performing S&P 500 component thus ... |
22,091 | 2023-10-29 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-48 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,092 | 2023-10-27 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-18 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,093 | 2023-10-27 00:00:00 UTC | AbbVie Q3 23 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q3-23-earnings-conference-call-at-9%3A00-am-et | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 27, 2023, to discuss Q3 23 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 27, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 27, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 27, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 27, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... |
22,094 | 2023-10-27 00:00:00 UTC | AbbVie raises profit forecast after Humira, newer drugs drive results beat | ABBV | https://www.nasdaq.com/articles/abbvie-raises-profit-forecast-after-humira-newer-drugs-drive-results-beat | null | null | Adds shares in paragraph 2
Oct 27 (Reuters) - AbbVie ABBV.N on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong demand for newer drugs.
The results and forecast lifted AbbVie's shares 2%... | AbbVie has been seeking to expand the use of newer immunology drugs Skyrizi and Rinvoq as it banks on them to make up for the expected drop in Humira sales. Adds shares in paragraph 2 Oct 27 (Reuters) - AbbVie ABBV.N on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a low... | Adds shares in paragraph 2 Oct 27 (Reuters) - AbbVie ABBV.N on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong demand for newer drugs. AbbVie reported $13.93 billion in quarterly revenu... | Adds shares in paragraph 2 Oct 27 (Reuters) - AbbVie ABBV.N on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong demand for newer drugs. The results and forecast lifted AbbVie's shares 2%... | Adds shares in paragraph 2 Oct 27 (Reuters) - AbbVie ABBV.N on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong demand for newer drugs. AbbVie reported $13.93 billion in quarterly revenu... |
22,095 | 2023-10-27 00:00:00 UTC | AbbVie Raises 2023 Adj. EPS Guidance; Announces 2024 Dividend Increase | ABBV | https://www.nasdaq.com/articles/abbvie-raises-2023-adj.-eps-guidance-announces-2024-dividend-increase | null | null | (RTTNews) - AbbVie (ABBV) said the company is raising adjusted EPS guidance for the full year 2023 from $10.86 - $11.06 to $11.19 - $11.23, which included an unfavorable impact of $0.27 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2023.
AbbVie increased its ... | (RTTNews) - AbbVie (ABBV) said the company is raising adjusted EPS guidance for the full year 2023 from $10.86 - $11.06 to $11.19 - $11.23, which included an unfavorable impact of $0.27 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2023. AbbVie increased its ... | (RTTNews) - AbbVie (ABBV) said the company is raising adjusted EPS guidance for the full year 2023 from $10.86 - $11.06 to $11.19 - $11.23, which included an unfavorable impact of $0.27 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2023. AbbVie increased its ... | (RTTNews) - AbbVie (ABBV) said the company is raising adjusted EPS guidance for the full year 2023 from $10.86 - $11.06 to $11.19 - $11.23, which included an unfavorable impact of $0.27 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2023. AbbVie said its board... | AbbVie increased its adjusted EPS guidance floor for the full year 2024 from $10.70 to $11.00, which excludes any impact from acquired IPR&D and milestones. As a result, AbbVie does not expect adjusted EPS for 2024 to be below $11.00 per share. (RTTNews) - AbbVie (ABBV) said the company is raising adjusted EPS guidance... |
22,096 | 2023-10-27 00:00:00 UTC | AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-and-revenues-beat-estimates | null | null | AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $3.66 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.15%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.93 billion for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 1.65%. Abb... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.93 billion for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 1.65%. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report To... | AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.93 billion for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 1.65%. Cli... | AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.93 billion for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 1.65%. Abb... |
22,097 | 2023-10-27 00:00:00 UTC | AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-beat-shares-down-despite-raised-view | null | null | AbbVie Inc. ABBV reported adjusted earnings of $2.95 per share for third-quarter 2023, beating the Zacks Consensus Estimate of $2.86. The reported earnings also exceeded the guidance of $2.76-$2.86. However, earnings declined 19.4% year over year.
ABBV’s revenues of $13.93 billion beat the Zacks Consensus Estimate of $... | Per the terms of the agreement, AbbVie shares profits earned from Epkinly sales in the United States and Japan while holding exclusive rights for other global territories. AbbVie Inc. ABBV reported adjusted earnings of $2.95 per share for third-quarter 2023, beating the Zacks Consensus Estimate of $2.86. ABBV’s revenue... | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Sandoz Group AG Sponsored ADR (SDZNY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV reported adju... | AbbVie’s oncology/hematology sales declined 8.6% on an operational basis to $1.51 billion in the quarter, as growth of Venclexta sales was more than offset by lower sales of Imbruvica. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVi... | AbbVie Inc. ABBV reported adjusted earnings of $2.95 per share for third-quarter 2023, beating the Zacks Consensus Estimate of $2.86. The drug’s sales, which reflects AbbVie’s share of profit from U.S. revenues, were $14 million. ABBV’s revenues of $13.93 billion beat the Zacks Consensus Estimate of $13.70 billion. |
22,098 | 2023-10-27 00:00:00 UTC | High-yield, deep-value AbbVie fell off the patent cliff and lived | ABBV | https://www.nasdaq.com/articles/high-yield-deep-value-abbvie-fell-off-the-patent-cliff-and-lived | null | null | Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company’s results but has done nothing to change its financial health, position, long-term outlook or ability to deliver value for investors. The stock discoun... | Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. AbbVie’s growth machine solid; Humira sales still strong Humira is a concern for AbbVie and its investors, but the signals from the data suggest the worst-case scenario is far from reality.... | So, AbbVie posted a 6% decline in YOY revenue, but it beat the Marketbeat.com consensus estimate by 160 basis points and is compounded by margin strength. Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. AbbVie’s growth machine solid; Hum... | AbbVie’s growth machine solid; Humira sales still strong Humira is a concern for AbbVie and its investors, but the signals from the data suggest the worst-case scenario is far from reality. The analysts leading AbbVie’s market higher As mixed as the analysts' AbbVie activity this year, the takeaway from the data is bul... | The analysts leading AbbVie’s market higher As mixed as the analysts' AbbVie activity this year, the takeaway from the data is bullish for stock prices. Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. AbbVie’s growth machine solid; Humir... |
22,099 | 2023-10-27 00:00:00 UTC | Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics | ABBV | https://www.nasdaq.com/articles/compared-to-estimates-abbvie-abbv-q3-earnings%3A-a-look-at-key-metrics | null | null | For the quarter ended September 2023, AbbVie (ABBV) reported revenue of $13.93 billion, down 6% over the same period last year. EPS came in at $2.95, compared to $3.66 in the year-ago quarter.
The reported revenue represents a surprise of +1.65% over the Zacks Consensus Estimate of $13.7 billion. With the consensus EPS... | For the quarter ended September 2023, AbbVie (ABBV) reported revenue of $13.93 billion, down 6% over the same period last year. Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Immunology- Skyrizi- International: ... | Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Immunology- Skyrizi- International: $251 million versus $280.66 million estimated by six analysts on average. For the quarter ended September 2023, AbbVie (ABBV) re... | Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Immunology- Skyrizi- International: $251 million versus $280.66 million estimated by six analysts on average. For the quarter ended September 2023, AbbVie (ABBV) re... | For the quarter ended September 2023, AbbVie (ABBV) reported revenue of $13.93 billion, down 6% over the same period last year. Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Immunology- Skyrizi- International: ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.